Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.6    
    

 
  HELICOS BIOSCIENCES CORPORATION    
    

2003 STOCK OPTION AND INCENTIVE PLAN
  last amended January 19, 2007 

1.    Purpose and Eligibility    

        The
purpose of this 2003 Stock Option and Incentive Plan (the "Plan)") of Helicos BioSciences Corporation (the "Company") is to provide stock options and other equity interests in the
Company (each an "Award") to employees, officers, directors, consultants and advisors of the Company and its Subsidiaries, all of whom are eligible to receive Awards under the Plan. Any person to whom
an Award has been granted under the Plan is called a "Participant". Additional definitions are contained in Section 8. 

2.    Administration    

        a.    Administration by Board of Directors.    The Plan will be administered by the Board of Directors of the Company
(the "Board"). The Board, in its sole discretion, shall have the authority to grant and amend Awards, to adopt, amend and repeal rules relating to the
Plan and to interpret and correct the provisions of the Plan and any Award. All decisions by the Board shall be final and binding on all interested persons. Neither the Company nor any member of the
Board shall be liable for any action or determination relating to the Plan. 

        b.    Appointment of Committees.    To the extent permitted by applicable law, the Board may delegate any or all of
its powers under the Plan to one or more committees or subcommittees of the Board (a "Committee"). All references in the Plan to the
"Board" shall mean such Committee or the Board. 

        c.    Delegation to Executive Officers.    To the extent permitted by applicable law, the Board may delegate to one or
more executive officers of the Company the power to grant Awards and exercise such other powers under the Plan as the Board may determine, provided that
the Board shall fix the maximum number of Awards to be granted and the maximum number of shares issuable to any one Participant pursuant to Awards granted by such executive officers. 

3.    Stock Available for Awards    

        a.    Number of Shares.    Subject to adjustment under Section 3(c), the aggregate number of shares of Common
Stock of the Company (the "Common Stock") that may be issued pursuant to the Plan is 20,576,382 shares. If any Award expires, or is terminated,
surrendered or forfeited, in whole or in part, the unissued Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. If shares of Common Stock issued
pursuant to the Plan are repurchased by, or are surrendered or forfeited to, the Company at no more than cost, such shares of Common Stock shall again be available for the grant of Awards under the
Plan; provided, however, that the cumulative number of such shares that may be so reissued under the Plan will not exceed 20,576,382 shares. Shares
issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares. 

        b.    Per-Participant Limit.    Subject to adjustment under Section 3(c), no Participant may be
granted Awards during any one fiscal year to purchase more than 6,393,501 shares of Common Stock. 

        c.    Adjustment to Common Stock.    In the event of any stock split, stock dividend, extraordinary cash dividend,
recapitalization, reorganization, merger, consolidation, combination, exchange of shares, liquidation, spin-off, split-up, or other similar change in capitalization or event,
(i) the number and class of securities available for Awards under the Plan and the per-Participant share limit, (ii) the number and class of securities, vesting schedule and
exercise price per share subject to each outstanding Option, (iii) the repurchase price per security subject to repurchase, and (iv) the terms of each other outstanding stock-based Award
shall be adjusted by the Company on an equitable or proportionate basis. If Section 7(e)(i) applies for any event, this Section 3(c) shall not be applicable. 

 

4.    Stock Options    

        a.    General.    The Board may grant options to purchase Common Stock (each, an
"Option") and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and
limitations applicable to the exercise of each Option and the Common Stock issued upon the exercise of each Option, including vesting provisions, repurchase provisions and restrictions relating to
applicable federal or state securities laws, as it considers advisable. 

        b.    Incentive Stock Options.    An Option that the Board intends to be an "incentive stock
option" as defined in Section 422 of the Code (an "Incentive Stock Option") shall be granted only to employees of the Company and shall be subject to and shall be
construed consistently with the requirements of Section 422 of the Code. The Board and the Company shall have no liability if an Option or any part thereof that is intended to be an Incentive
Stock Option does not qualify as such. An Option or any part thereof that does not qualify as an Incentive Stock Option is referred to herein as a "Nonstatutory Stock
Option." 

        c.    Exercise Price.    The Board shall establish the exercise price (or determine the method by which the exercise
price shall be determined) at the time each Option is granted and specify it in the applicable option agreement. 

        d.    Duration of Options.    Each Option shall be exercisable at such times and subject to such terms and conditions
as the Board may specify in the applicable option agreement. 

        e.    Exercise of Option.    Options may be exercised only by delivery to the Company of a written notice of exercise
signed by the proper person together with payment in full as specified in Section 4(f) for the number of shares for which the Option is exercised. 

        f.    Payment Upon Exercise.    Common Stock purchased upon the exercise of an Option shall be paid for by one or any
combination of the following forms of payment: 

          (i)  by
check payable to the order of the Company; 

         (ii)  except
as otherwise explicitly provided in the applicable option agreement, and only if the Common Stock is then publicly traded, delivery of an irrevocable and
unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price, or delivery by the Participant to the Company of a copy of irrevocable
and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price; or 

        (iii)  to
the extent explicitly provided in the applicable option agreement, by (x) delivery of shares of Common Stock owned by the Participant valued at fair market
value (as determined by the Board or as determined pursuant to the applicable option agreement), (y) delivery of a promissory note of the Participant to the Company (and delivery to the Company
by the Participant of a check in an amount equal to the par value of the shares purchased), or (z) payment of such other lawful consideration as the Board may determine. 

5.    Restricted Stock    

        a.    Grants.    The Board may grant Awards entitling recipients to acquire shares of Common Stock, subject to
(i) delivery to the Company by the Participant of cash or other lawful consideration in an amount at least equal to the par value of the shares purchased, and (ii) the right of the
Company to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant in the event that conditions specified by the Board in the applicable Award
are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award (each, a "Restricted Stock
Award"). 

2

 

        b.    Terms and Conditions.    The Board shall determine the terms and conditions of any such Restricted Stock Award.
Any stock certificates issued in respect of a Restricted Stock Award shall be registered in the name of the Participant and, unless otherwise determined by the Board, deposited by the Participant,
together with a stock power endorsed in blank, with the Company (or its designee). After the expiration of the applicable restriction periods, the Company (or such designee) shall deliver the
certificates no longer subject to such restrictions to the Participant or, if the Participant has died, to the beneficiary designated by a Participant, in a manner determined by the Board, to receive
amounts due or exercise rights of the Participant in the event of the Participant's death (the "Designated Beneficiary"). In the absence of an effective
designation by a Participant, Designated Beneficiary shall mean the Participant's estate. 

6.    Other Stock-Based Awards    

        The
Board shall have the right to grant other Awards based upon the Common Stock having such terms and conditions as the Board may determine, including, without limitation, the grant of
shares based upon certain conditions, the grant of securities convertible into Common Stock and the grant of stock appreciation rights, phantom stock awards or stock units. 

7.    General Provisions Applicable to Awards    

        a.    Transferability of Awards.    Except as the Board may otherwise determine or provide in an Award, Awards shall
not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and
distribution, and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, shall include references to
authorized transferees. 

        b.    Documentation.    Each Award under the Plan shall be evidenced by a written instrument in such form as the Board
shall determine or as executed by an officer of the Company pursuant to authority delegated by the Board. Each Award may contain terms and conditions in addition to those set forth in the Plan  provided that such terms and conditions do not contravene the provisions of the Plan. 

        c.    Board Discretion.    The terms of each type of Award need not be identical, and the Board need not treat
Participants uniformly. 

        d.    Termination of Status.    The Board shall determine the effect on an Award of the disability, death, retirement,
authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant's legal
representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award. 

        e.    Acquisition of the Company    

        (i)    Consequences of an Acquisition.    Upon the consummation of an Acquisition, the Board or the board of directors
of the surviving or acquiring entity (as used in this Section 7(e)(i), also the "Board"), shall, as to outstanding Awards (on the same basis or
on different bases as the Board shall specify), make appropriate provision for the continuation of such Awards by the Company or the assumption of such Awards by the surviving or acquiring entity and
by substituting on an equitable basis for the shares then subject to such Awards either (a) the consideration payable with respect to the outstanding shares of Common Stock in connection with
the Acquisition, (b) shares of stock of the surviving or acquiring corporation or (c) such other securities or other consideration as the Board deems appropriate, the fair market value
of which (as determined by the Board in its sole discretion) shall not materially differ from the fair market value of the shares of Common Stock subject to such Awards immediately preceding the 

3

 

Acquisition.
In addition to or in lieu of the foregoing, with respect to outstanding Options, the Board may, on the same basis or on different bases as the Board shall specify, upon written notice to
the affected optionees, provide that one or more Options then outstanding must be exercised, in whole or in part, within a specified number of days of the date of such notice, at the end of which
period such Options shall terminate, or provide that one or more Options then outstanding, in whole or in part, shall be terminated in exchange for a cash payment equal to the excess of the fair
market value (as determined by the Board in its sole discretion) for the shares subject to such Options over the exercise price thereof; provided,
however, that before terminating any portion of an Option that is not vested or exercisable (other than in exchange for a cash payment), the Board must first accelerate in full
the exercisability of the portion that is to be terminated. Unless otherwise determined by the Board (on the same basis or on different bases as the Board shall specify), any repurchase rights or
other rights of the Company that relate to an Option or other Award shall continue to apply to consideration, including cash, that has been substituted, assumed or amended for an Option or other Award
pursuant to this paragraph. The Company may hold in escrow all or any portion of any such consideration in order to effectuate any continuing restrictions. 

        (ii)    Acquisition Defined.    An "Acquisition" shall mean:
(x) the sale of the Company by merger in which the shareholders of the Company in their capacity as such no longer own a majority of the outstanding equity securities of the Company (or its
successor); or (y) any sale of all or substantially all of the assets or capital stock of the Company (other than in a spin-off or similar transaction) or (z) any other
acquisition of the business of the Company, as determined by the Board. 

        (iii)    Assumption of Options Upon Certain Events.    In connection with a merger or consolidation of an entity with
the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards under the Plan in substitution for stock and stock-based awards issued by such entity or an
affiliate thereof. The substitute Awards shall be granted on such terms and conditions as the Board considers appropriate in the circumstances. 

        f.    Withholding.    Each Participant shall pay to the Company, or make provisions satisfactory to the Company for
payment of, any taxes required by law to be withheld in connection with Awards to such Participant no later than the date of the event creating the tax liability. The Board may allow Participants to
satisfy such tax obligations in whole or in part by transferring shares of Common Stock,
including shares retained from the Award creating the tax obligation, valued at their fair market value (as determined by the Board or as determined pursuant to the applicable option agreement). The
Company may, to the extent permitted by law, deduct any such tax obligations from any payment of any kind otherwise due to a Participant. 

        g.    Amendment of Awards.    The Board may amend, modify or terminate any outstanding Award including, but not
limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option,  provided
that the Participant's consent to such action shall be required unless the Board determines that the action, taking into account any related
action, would not materially and adversely affect the Participant. 

        h.    Conditions on Delivery of Stock.    The Company will not be obligated to deliver any shares of Common Stock
pursuant to the Plan or to remove restrictions from shares previously delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of the Company,
(ii) in the opinion of the Company's counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws
and any applicable stock exchange or stock market rules and regulations, and (iii) the Participant has 

4

 

executed
and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. 

        i.    Acceleration.    The Board may at any time provide that any Options shall become immediately exercisable in full
or in part, that any Restricted Stock Awards shall be free of some or all restrictions, or that any other stock-based Awards may become exercisable in full or in part or free of some or all
restrictions or conditions, or otherwise realizable in full or in part, as the case may be, despite the fact that the foregoing actions may (i) cause the application of Sections 280G and 4999
of the Code if a change in control of the Company occurs, or (ii) disqualify all or part of the Option as an Incentive Stock Option. In the event of the acceleration of the exercisability of
one or more outstanding Options, including pursuant to paragraph (e)(i), the Board may provide, as a condition of full exercisability of any or all such Options, that the Common Stock or other
substituted consideration, including cash, as to which exercisability has been accelerated shall be restricted and subject to forfeiture back to the Company at the option of the Company at the cost
thereof upon termination of employment or other relationship, with the timing and other terms of the vesting of such restricted stock or other consideration being equivalent to the timing and other
terms of the superseded exercise schedule of the related Option. 

8.    Miscellaneous    

        a.    Definitions.    

          (i)  "Company," for purposes of eligibility under the Plan, shall include any present or future subsidiary corporations of
Helicos BioSciences Corporation, as defined in Section 424(f) of the Code (a "Subsidiary"), and any present or future parent corporation of
Helicos BioSciences Corporation, as defined in Section 424(e) of the Code. For purposes of Awards other than Incentive Stock Options, the term
"Company" shall include any other business venture in which the Company has a direct or indirect significant interest, as determined by the Board in its
sole discretion. 

         (ii)  "Code" means the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder. 

        (iii)  "employee" for purposes of eligibility under the Plan (but not for purposes of Section 4(b)) shall include a
person to whom an offer of employment has been extended by the Company. 

        b.    No Right To Employment or Other Status.    No person shall have any claim or right to be granted an Award, and
the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time
to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan. 

        c.    No Rights As Stockholder.    Subject to the provisions of the applicable Award, no Participant or Designated
Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder thereof. 

        d.    Effective Date and Term of Plan.    The Plan shall become effective on the date on which it is adopted by the
Board. No Awards shall be granted under the Plan after the completion of ten years from the date on which the Plan was adopted by the Board, but Awards previously granted may extend beyond that date. 

        e.    Amendment of Plan.    The Board may amend, suspend or terminate the Plan or any portion thereof at any time. 

5

 

        f.    Governing Law.    The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted
in accordance with the laws of Massachusetts, without regard to any applicable conflicts of law. 

Adopted
by the Board of Directors on

November 17, 2003 

Approved
by the stockholders on

June 29, 2004 

6

HELICOS BIOSCIENCES CORPORATION 

NON-QUALIFIED STOCK OPTION AGREEMENT  

        Helicos BioSciences Corporation (the "Company") hereby grants the following stock option pursuant to its 2003
Stock Option and Incentive Plan. The terms and conditions attached hereto are also a part hereof. 

	Name of optionee (the "Optionee"):	 	 
	

Date of this option grant:	
 	

 
	

Number of shares of the Company's Common Stock subject to this option ("Shares"):	
 	

 
	

Option exercise price per share:	
 	

 
	

Number, if any, of Shares that may be purchased on or after the grant date:	
 	

 
	

Shares that are subject to vesting schedule:	
 	

 
	

Vesting Start Date:	
 	

 
	

Vesting Schedule:	
 	

 
	

One year from Vesting Start Date:	
 	

25% of Shares
	

The first business day of each month following the first anniversary of the Vesting Start Date:	
 	

an additional 2.0833333% of the Shares

        This
option satisfies in full all commitments that the Company has to the Optionee with respect to the issuance of stock, stock options or other equity securities. 

	

 	
 	

Helicos BioSciences Corporation
	

	
 	

By:	

	Signature of Optionee	 	 	Name of Officer:
	    
	 	 	Title:
	Street Address	 	 	 
	    
 City/State/Zip Code	 	 	 

 
 

HELICOS BIOSCIENCES CORPORATION    
NON-QUALIFIED STOCK OPTION AGREEMENT—INCORPORATED TERMS AND CONDITIONS    
    

        1.    Grant Under Plan.    This option is granted pursuant to and is governed by the Company's 2003 Stock Option and
Incentive Plan (the "Plan") and, unless the context otherwise requires, terms used herein shall have the same meaning as in the Plan. 

        2.    Grant as Non-Qualified Stock Option.    This option is a non-statutory stock option and
is not intended to qualify as an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended, and the regulations thereunder (the
"Code"). 

        3.    Vesting of Option if Business Relationship Continues.    The Optionee may exercise this option on or after the
date of this option grant for the number of shares of Common Stock, if any, set forth on the cover page hereof. If the Optionee has continuously maintained a Business Relationship (as defined below)
with the Company through the dates listed on the vesting schedule set forth on the cover page hereof, the Optionee may exercise this option for the additional number of shares of Common Stock set
opposite the applicable vesting date. Notwithstanding the foregoing, the Board may, in its discretion, accelerate the date that any installment of this option becomes exercisable. The foregoing rights
are cumulative and (subject to Sections 4 or 5 hereof if the optionee ceases to maintain a Business Relationship with the Company) may be exercised only before the date which is ten years from the
date of this option grant. For the purposes hereof, "Business Relationship" means service to the Company or its successor in the capacity of an employee, officer, director or consultant. 

        4.    Termination of Business Relationship.    

        (a)    Termination.    If the Optionee's Business Relationship with the Company ceases, other than by reason of death
or disability as defined in Section 5 or Termination for Cause as defined in Section 4(d) no further installments of this option shall become exercisable, and this option shall expire
(may no longer be exercised) after the passage of 180 days from the date of termination, but in no event later than the scheduled expiration date. Any determination under this agreement as to
the status of a Business Relationship or other matters referred to above shall be made in good faith by the Board of Directors of the Company. 

        (b)    Employment Status.    For purposes hereof, with respect to employees of the Company, employment shall not be
considered as having terminated during any leave of absence if such leave of absence has been approved in writing by the Company and if such written approval contractually obligates the Company to
continue the employment of the Optionee after the approved period of absence; in the event of such an approved leave of absence, vesting of this option shall be suspended (and the period of the leave
of absence shall be added to all vesting dates) unless otherwise provided in the Company's written approval of the leave of absence. This option shall not be affected by any change of employment
within or among the Company and its Subsidiaries so long as the Optionee continuously remains an employee of the Company or any Subsidiary. 

        (c)    Termination for Cause.    If the Business Relationship of the Optionee is terminated for Cause (as defined
below), this option may no longer be exercised from and after the Optionee's receipt of written notice of such termination. 

        (d)    Definition of Cause.    "Cause" means: (i) a breach of fiduciary duty or confidentiality obligations to
the Company by the Optionee or (ii) the commission by the Optionee of illegal conduct relating to the Company. 

        5.    Death; Disability.    

        (a)    Death.    Upon the death of the Optionee while the Optionee is maintaining a Business Relationship with the
Company, this option may be exercised, to the extent otherwise exercisable on the date of the Optionee's death, by the Optionee's estate, personal representative or 

beneficiary
to whom this option has been transferred pursuant to Section 10, only at any time within 180 days after the date of death, but not later than the scheduled expiration date. 

        (b)    Disability.    If the Optionee ceases to maintain a Business Relationship with the Company by reason of his or
her disability, this option may be exercised, to the extent otherwise exercisable on the date of cessation of the Business Relationship, only at any time within 180 days after such cessation of
the Business Relationship, but not later than the scheduled expiration date. For purposes hereof, "disability" means "permanent
and total disability" as defined in Section 22(e)(3) of the Code. 

        6.    Partial Exercise.    This option may be exercised in part at any time and from time to time within the above
limits, except that this option may not be exercised for a fraction of a share. 

        7.    Payment of Exercise Price.    

        (a)    Payment Options.    The exercise price shall be paid by one or any combination of the following forms of
payment that are applicable to this option, as indicated on the cover page hereof: 

	(i)
	by
check payable to the order of the Company; or

	(ii)
	delivery
of an irrevocable and unconditional undertaking, satisfactory in form and substance to the Company, by a creditworthy broker to deliver promptly to the Company
sufficient funds to pay the exercise price, or delivery by the Optionee to the Company of a copy of irrevocable and unconditional instructions, satisfactory in form and substance to the Company, to a
creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price; or

	(iii)
	subject
to Section 7(b) below, if the Common Stock is then traded on a national securities exchange or on the Nasdaq National Market (or successor trading
system), by delivery of shares of Common Stock having a fair market value equal as of the date of exercise to the option price; or 

        In
the case of (iii) above, fair market value as of the date of exercise shall be determined as of the last business day for which such prices or quotes are available prior to the
date of exercise and shall mean (i) the last reported sale price (on that date) of the Common Stock on the principal national securities exchange on which the Common Stock is traded, if the
Common Stock is then traded on a national securities exchange; or (ii) the last reported sale price (on that date) of the Common Stock on the Nasdaq National Market (or successor trading
system), if the Common Stock is not then traded on a national securities exchange. 

        (b)    Limitations on Payment by Delivery of Common Stock.    If Section 7(a)(iii) is applicable, and if
the Optionee delivers Common Stock held by the Optionee ("Old Stock") to the Company in full or partial payment of the exercise price and the Old Stock
so delivered is subject to restrictions or limitations imposed by agreement between the Optionee and the Company, an equivalent number of Shares shall be subject to all restrictions and limitations
applicable to the Old Stock to the extent that the Optionee paid for the Shares by delivery of Old Stock, in addition to any restrictions or limitations imposed by this agreement. Notwithstanding the
foregoing, the Optionee may not pay any part of the exercise price hereof by transferring Common Stock to the Company unless such Common Stock has been owned by the Optionee free of any substantial
risk of forfeiture for at least six months. 

        8.    Securities Laws Restrictions on Resale.    Until registered under the Securities Act of 1933, as amended, or any
successor statute (the "Securities Act"), the Shares will be illiquid and will be deemed to be "restricted securities" for purposes of the Securities
Act. Accordingly, such shares must be sold in compliance with the registration requirements of the Securities Act or an exemption therefrom and may need to be held indefinitely. Unless the Shares have
been registered under the Securities Act, each certificate evidencing any of the Shares shall bear a restrictive legend specified by the Company. 

        9.    Method of Exercising Option.    Subject to the terms and conditions of this agreement, this option may be
exercised by written notice to the Company at its principal executive office, or to such transfer agent as the Company shall designate. Such notice shall state the election to exercise this option and
the number of Shares for which it is being exercised and shall be signed by the person or persons so exercising this option. Such notice shall be accompanied by payment of the full purchase price of
such shares, and the Company shall deliver a certificate or certificates representing such shares as soon as practicable after the notice shall be received. Such certificate or certificates shall be
registered in the name of the person or persons so exercising this option (or, if this option shall be exercised by the Optionee and if the Optionee shall so request in the notice exercising this
option, shall be registered in the name of the Optionee and another person jointly, with right of survivorship). In the event this option shall be exercised, pursuant to Section 5 hereof, by
any person or persons other than the Optionee, such notice shall be accompanied by appropriate proof of the right of such person or persons to exercise this option. 

        10.    Option Not Transferable.    This option is not transferable or assignable except by will or by the laws of
descent and distribution. During the Optionee's lifetime only the Optionee can exercise this option. 

        11.    No Obligation to Exercise Option.    The grant and acceptance of this option imposes no obligation on the
Optionee to exercise it. 

        12.    No Obligation to Continue Business Relationship.    Neither the Plan, this agreement, nor the grant of this
option imposes any obligation on the Company to continue the Optionee in employment or other Business Relationship. 

        13.    Adjustments.    Except as is expressly provided in the Plan with respect to certain changes in the
capitalization of the Company, no adjustment shall be made for dividends or similar rights for which the record date is prior to such date of exercise. 

        14.    Withholding Taxes.    If the Company in its discretion determines that it is obligated to withhold any tax in
connection with the exercise of this option, or in connection with the transfer of, or the lapse of restrictions on, any Common Stock or other property acquired pursuant to this option, the Optionee
hereby agrees that the Company may withhold from the Optionee's wages or other remuneration the appropriate amount of tax. At the discretion of the Company, the amount required to be withheld may be
withheld in cash from such wages or other remuneration or in kind from the Common Stock or other property otherwise deliverable to the Optionee on exercise of this option. The Optionee further agrees
that, if the Company does not withhold an amount from the Optionee's wages or other remuneration sufficient to satisfy the withholding obligation of the Company, the Optionee will make reimbursement
on demand, in cash, for the amount underwithheld. 

        15.    Restrictions on Transfer; Company's Right of First Refusal.    

        (a)    Exercise of Right.    Shares may not be transferred without the Company's written consent except by will, by
the laws of descent and distribution or in accordance with the further provisions of this Section 15. If the Optionee desires to transfer all or any part of the Shares to any person other than
the Company (an "Offeror"), the Optionee shall: (i) obtain in writing an irrevocable and unconditional bona
fide offer (the "Offer") for the purchase thereof from the Offeror; and (ii) give written notice (the
"Option Notice") to the Company setting forth the Optionee's desire to transfer such shares, which Option Notice shall be accompanied by a photocopy of
the Offer and shall set forth at least the name and address of the Offeror and the price and terms of the Offer. Upon receipt of the Option Notice, the Company shall have an assignable option to
purchase any or all of such Shares (the "Offered Shares") specified in the Option Notice, such option to be exercisable by giving, within 15 days
after receipt of the Option Notice, a written counter-notice to the Optionee. If the Company elects to purchase all of such Offered Shares, it shall be obligated to purchase, and the Optionee shall be
obligated to sell to the Company or its assignee, such Offered Shares at the price and terms indicated in the Offer within 30 days from the date of delivery by the Company of such
counter-notice. To the extent that the consideration proposed to be paid by 

the
Offeror for the shares consists of property other than cash or a promissory note, the consideration required to be paid by the Company may consist of cash equal to the fair market value of such
property, as determined in good faith by the Board of Directors of the Company. 

        (b)    Sale of Shares to Offeror.    The Optionee may, for 60 days after the expiration of the
30-day option period as set forth in Section 15(a), sell to the Offeror, pursuant to the terms of the Offer, all of such Offered Shares not purchased or agreed to be purchased by
the Company or its assignee; provided, however, that the Optionee shall not sell such Shares to such Offeror if such Offeror is a competitor of the
Company and the Company gives written notice to the Optionee, within 30 days of its receipt of the Option Notice, stating that the Optionee shall not sell his or her Shares to such Offeror; and  provided, further,
 that prior to the sale of such Shares to an Offeror, such Offeror shall execute an agreement with the Company pursuant to which such
Offeror agrees to be subject to the restrictions set forth in this Section 15. If any or all of such Shares are not sold pursuant to an Offer within the time permitted above, the unsold Shares
shall remain subject to the terms of this Section 15. 

        (c)    Failure to Deliver Shares.    If the Optionee (or his or her legal representative) who has become obligated to
sell Shares hereunder shall fail to deliver such shares to the Company in accordance with the terms of this agreement, the Company may, at its option, in addition to all other remedies it may have,
mail to the Optionee the purchase price for such shares as is herein specified. Thereupon, the Company: (i) shall cancel on its books the certificate or certificates representing such Shares to
be sold; and (ii) shall issue, in lieu thereof, a new certificate or certificates in the name of the Company representing such Shares (or cancel such Shares), and thereupon all of such
Optionee's rights in and to such Shares shall terminate. 

        (d)    Expiration of Company's Right of First Refusal and Transfer Restrictions.    The first refusal rights of the
Company and the transfer restrictions set forth in this Section 15 shall expire as to Shares on the earliest to occur of (i) the tenth anniversary of the date of this agreement,
(ii) immediately prior to the
closing of a public offering of Common Stock by the Company pursuant to an effective registration statement filed under the Securities Act, or (iii) the occurrence of an Acquisition that is not
a Private Transaction. In addition, if the Company and the Optionee are parties to an agreement containing first refusal provisions similar to the foregoing, such other agreement shall control. 

        16.    Lock-up Agreement.    The Optionee agrees that in the event that the Company effects an initial
underwritten public offering of Common Stock registered under the Securities Act, the Shares may not be sold, offered for sale or otherwise disposed of, directly or indirectly, without the prior
written consent of the managing underwriter(s) of the offering, for such period of time after the execution of an underwriting agreement in connection with such offering that all of the Company's then
directors and executive officers agree to be similarly bound. 

        17.    Arbitration.    Any dispute, controversy, or claim arising out of, in connection with, or relating to the
performance of this agreement or its termination shall be settled by arbitration in the Commonwealth of Massachusetts, pursuant to the rules then obtaining of the American Arbitration Association. Any
award shall be final, binding and conclusive upon the parties and a judgment rendered thereon may be entered in any court having jurisdiction thereof. 

        18.    Provision of Documentation to Optionee.    By signing this agreement the Optionee acknowledges receipt of a
copy of this agreement and a copy of the Plan. 

        19.    Miscellaneous.    

        (a)    Notices.    All notices hereunder shall be in writing and shall be deemed given when sent by mail, if to the
Optionee, to the address set forth below or at the address shown on the records of the Company, and if to the Company, to the Company's principal executive offices, attention of the Corporate
Secretary. 

        (b)    Entire Agreement; Modification.    This agreement constitutes the entire agreement between the parties relative
to the subject matter hereof, and supersedes all proposals, written or oral, and all other communications between the parties relating to the subject matter of this agreement. This agreement may be
modified, amended or rescinded only by a written agreement executed by both parties. 

        (c)    Fractional Shares.    If this option becomes exercisable for a fraction of a share because of the adjustment
provisions contained in the Plan, such fraction shall be rounded down. 

        (d)    Issuances of Securities; Changes in Capital Structure.    Except as expressly provided herein or in the Plan,
no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect
to, the number or price of shares subject to this option. No adjustments need be made for dividends paid in cash or in property other than securities of the Company. If there shall be any change in
the Common Stock of the Company through merger, consolidation, reorganization, recapitalization, stock dividend, stock split, combination or exchange of shares, spin-off,
split-up or other similar change in capitalization or event, the restrictions contained in this agreement shall apply with equal force to additional and/or substitute securities, if any,
received by the Optionee in exchange for, or by virtue of his or her ownership of, Shares, except as otherwise determined by the Board. 

        (e)    Severability.    The invalidity, illegality or unenforceability of any provision of this agreement shall in no
way affect the validity, legality or enforceability of any other provision. 

        (f)    Successors and Assigns.    This agreement shall be binding upon and inure to the benefit of the parties hereto
and their respective successors and assigns, subject to the limitations set forth in Section 10 hereof. 

        (g)    Governing Law.    This agreement shall be governed by and interpreted in accordance with the laws of the
Commonwealth of Massachusetts, without giving effect to the principles of the conflicts of laws thereof. 

HELICOS BIOSCIENCES CORPORATION 

INCENTIVE STOCK OPTION AGREEMENT  

        Helicos BioSciences Corporation (the "Company") hereby grants the following stock option pursuant to its 2003
Stock Option and Incentive Plan. The terms and conditions attached hereto are also a part hereof. 

	Name of employee (the "Employee"):	 	 
	

Date of this option grant:	
 	

 
	

Number of shares of the Company's Common Stock subject to this option ("Shares"):	
 	

 
	

Option exercise price per share:	
 	

 
	

Number, if any, of Shares that may be purchased on or after the grant date:	
 	

 
	

Shares that are subject to vesting schedule A:	
 	

 
	

Vesting Start Date:	
 	

 
	

Shares that are subject to vesting schedule B:	
 	

 
	

Vesting Start Date:	
 	

 
	

Vesting Schedule A:	
 	

 
	

One year from Vesting Start Date:	
 	

25% of Shares
	

The first business day of each month following the first anniversary of the Vesting Start Date:	
 	

an additional 2.0833333% of Shares
	

Vesting Schedule A:	
 	

 
	

The first business day of each month:	
 	

2.7777778%

        This
option satisfies in full all commitments that the Company has to the Optionee with respect to the issuance of stock, stock options or other equity securities. 

	

 	
 	

Helicos BioSciences Corporation
	

    
	
 	

By:	

    

	Signature of Employee	 	 	Name of Officer:
	    
	 	 	Title:
	Street Address	 	Date:	    

	    
 City/State/Zip Code	 	 	 

Helicos BioSciences Corporation 

INCENTIVE STOCK OPTION AGREEMENT—INCORPORATED TERMS AND CONDITIONS  

        1.    Grant Under Plan.    This option is granted pursuant to and is governed by the Company's 2003 Stock Option and
Incentive Plan (the "Plan") and, unless the context otherwise requires, terms used herein shall have the same meaning as in the Plan. 

        2.    Grant as Incentive Stock Option.    This option is intended to qualify as an incentive stock option under
Section 422 of the Internal Revenue Code of 1986, as amended, and the regulations thereunder (the "Code"). 

        3.    Vesting of Option if Employment Continues.    The Employee may exercise this option on or after the date of this
option grant for the number of shares of Common Stock, if any, set forth on the cover page hereof. If the Employee has remained continuously employed by the Company through the dates listed on the
vesting schedule set forth on the cover page hereof, the Employee may exercise this option for the additional number of shares of Common Stock set opposite the applicable vesting date. Notwithstanding
the foregoing, the Board may, in its discretion, accelerate the date that any installment of this option becomes exercisable. The foregoing rights are cumulative and (subject to Sections 4 or 5 hereof
if the Employee ceases to be employed by the Company) may be exercised only before the date which is ten years from the date of this option grant. 

        4.    Termination of Employment.    

        (a)    Termination.    If the Employee ceases to be employed by the Company, other than by reason of death or
disability as defined in Section 5 or termination for Cause as defined in Section 4(c), no further installments of this option shall become exercisable, and this option shall expire (may
no longer be exercised) after the passage of 90 days. For purposes hereof, employment shall not be considered as having terminated during any leave of absence if such leave of absence has been
approved in writing by the Company and if such written approval contractually obligates the Company to continue the employment of the Employee after the approved period of absence; in the event of
such an approved leave of absence, vesting of this option shall be suspended (and the period of the leave of absence shall be added to all vesting dates) unless otherwise provided in the Company's
written approval of the leave of absence. For purposes hereof, employment shall include a consulting arrangement between the Employee and the Company that immediately follows termination of
employment, but only if so stated in a written consulting agreement executed by the Company that specifically refers to this option. This option shall not be affected by any change of employment
within or among the Company and its Subsidiaries so long as the Employee continuously remains an employee of the Company or any Subsidiary. 

        (b)    Termination for Cause.    If employment of the Employee is terminated for Cause (as defined below), this option
may no longer be exercised from and after the Employee's receipt of written notice of such termination. 

        (c)    Definition of Cause.    "Cause" means: (i) a breach of
fiduciary duty or confidentiality obligations to the Company by the Employee or (ii) the commission by the Employee of illegal conduct relating to the Company. 

        5.    Death; Disability.    

        (a)    Death.    Upon the death of the Employee while the Employee is in the employ of the Company, this option may be
exercised, to the extent otherwise exercisable on the date of the Employee's death, by the Employee's estate, personal representative or beneficiary to whom this option has been transferred pursuant
to Section 10, only at any time within 180 days after the date of death, but not later than the scheduled expiration date. 

        (b)    Disability.    If the Employee ceases to be employed by the Company by reason of his or her disability, this
option may be exercised, to the extent otherwise exercisable on the date of cessation of employment, only at any time within 180 days after such cessation of employment, but 

not
later than the scheduled expiration date. For purposes hereof, "disability" means "permanent and total
disability" as defined in Section 22(e)(3) of the Code. 

        6.    Partial Exercise.    This option may be exercised in part at any time and from time to time within the above
limits, except that this option may not be exercised for a fraction of a share. 

        7.    Payment of Exercise Price.    

        (a)    Payment Options.    The exercise price shall be paid by one or any combination of the following forms of
payment that are applicable to this option, as indicated on the cover page hereof: 

	(i)
	by
check payable to the order of the Company; or

	(ii)
	delivery
of an irrevocable and unconditional undertaking, satisfactory in form and substance to the Company, by a creditworthy broker to deliver promptly to the Company
sufficient funds to pay the exercise price, or delivery by the Employee to the Company of a copy of irrevocable and unconditional instructions, satisfactory in form and substance to the Company, to a
creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price; or

	(iii)
	subject
to Section 7(b) below, if the Common Stock is then traded on a national securities exchange or on the Nasdaq National Market (or successor trading
system), by delivery of shares of Common Stock having a fair market value equal as of the date of exercise to the option price. 

        In
the case of (iii) above, fair market value as of the date of exercise shall be determined as of the last business day for which such prices or quotes are available prior to the
date of exercise and shall mean (i) the last reported sale price (on that date) of the Common Stock on the principal national securities exchange on which the Common Stock is traded, if the
Common Stock is then traded on a national securities exchange; or (ii) the last reported sale price (on that date) of the Common Stock on the Nasdaq National Market (or successor trading
system), if the Common Stock is not then traded on a national securities exchange. 

        (b)    Limitations on Payment by Delivery of Common Stock.    If Section 7(a)(iii) is applicable, and if
the Employee delivers Common Stock held by the Employee ("Old Stock") to the Company in full or partial payment of the exercise price and the Old Stock
so delivered is subject to restrictions or limitations imposed by agreement between the Employee and the Company, an equivalent number of Shares shall be subject to all restrictions and limitations
applicable to the Old Stock to the extent that the Employee paid for the Shares by delivery of Old Stock, in addition to any restrictions or limitations imposed by this agreement. Notwithstanding the
foregoing, the Employee may not pay any part of the exercise price hereof by transferring Common Stock to the Company unless such Common Stock has been owned by the Employee free of any substantial
risk of forfeiture for at least six months. 

        8.    Securities Laws Restrictions on Resale.    Until registered under the Securities Act of 1933, as amended, or any
successor statute (the "Securities Act"), the Shares will be illiquid and will be deemed to be "restricted securities" for purposes of the Securities
Act. Accordingly, such shares must be sold in compliance with the registration requirements of the Securities Act or an exemption therefrom and may need to be held indefinitely. Unless the Shares have
been registered under the Securities Act, each certificate evidencing any of the Shares shall bear a restrictive legend specified by the Company. 

        9.    Method of Exercising Option.    Subject to the terms and conditions of this agreement, this option may be
exercised by written notice to the Company at its principal executive office, or to such transfer agent as the Company shall designate. Such notice shall state the election to exercise this option and
the number of Shares for which it is being exercised and shall be signed by the person or persons so exercising this option. Such notice shall be accompanied by payment of the full purchase price of
such shares, and the Company shall deliver a certificate or certificates representing such shares as soon as practicable after the notice shall be received. Such certificate or certificates shall be 

registered
in the name of the person or persons so exercising this option (or, if this option shall be exercised by the Employee and if the Employee shall so request in the notice exercising this
option, shall be registered in the name of the Employee and another person jointly, with right of survivorship). In the event this option shall be exercised, pursuant to Section 5 hereof, by
any person or persons other than the Employee, such notice shall be accompanied by appropriate proof of the right of such person or persons to exercise this option. 

        10.    Option Not Transferable.    This option is not transferable or assignable except by will or by the laws of
descent and distribution. During the Employee's lifetime only the Employee can exercise this option. 

        11.    No Obligation to Exercise Option.    The grant and acceptance of this option imposes no obligation on the
Employee to exercise it. 

        12.    No Obligation to Continue Employment.    Neither the Plan, this agreement, nor the grant of this option imposes
any obligation on the Company to continue the Employee in employment. 

        13.    Adjustments.    Except as is expressly provided in the Plan with respect to certain changes in the
capitalization of the Company, no adjustment shall be made for dividends or similar rights for which the record date is prior to such date of exercise. 

        14.    Withholding Taxes.    If the Company in its discretion determines that it is obligated to withhold any tax in
connection with the exercise of this option, or in connection with the transfer of, or the lapse of restrictions on, any Common Stock or other property acquired pursuant to this option, the Employee
hereby agrees that the Company may withhold from the Employee's wages or other remuneration the appropriate amount of tax. At the discretion of the Company, the amount required to be withheld may be
withheld in cash from such wages or other remuneration or in kind from the Common Stock or other property otherwise deliverable to the Employee on exercise of this option. The Employee further agrees
that, if the Company does not withhold an amount from the Employee's wages or other remuneration sufficient to satisfy the withholding obligation of the Company, the Employee will make reimbursement
on demand, in cash, for the amount underwithheld. 

        15.    Restrictions on Transfer; Company's Right of First Refusal.    

        (a)    Exercise of Right.    Shares may not be transferred without the Company's written consent except by will, by
the laws of descent and distribution or in accordance with the further provisions of this Section 15. If the Employee desires to transfer all or any part of the Shares to any person other than
the Company (an "Offeror"), the Employee shall: (i) obtain in writing an irrevocable and unconditional bona
fide offer (the "Offer") for the purchase thereof from the Offeror; and (ii) give written notice (the
"Option Notice") to the Company setting forth the Employee's desire to transfer such shares, which Option Notice shall be accompanied by a photocopy of
the Offer and shall set forth at least the name and address of the Offeror and the price and terms of the Offer. Upon receipt of the Option Notice, the Company shall have an assignable option to
purchase any or all of such Shares (the "Offered Shares") specified in the Option Notice, such option to be exercisable by giving, within 15 days
after receipt of the Option Notice, a written counter-notice to the Employee. If the Company elects to purchase all of such Offered Shares, it shall be obligated to purchase, and the Employee shall be
obligated to sell to the Company or its assignee, such Offered Shares at the price and terms indicated in the Offer within 30 days from the date of delivery by the Company of such
counter-notice. To the extent that the consideration proposed to be paid by the Offeror for the shares consists of property other than cash or a promissory note, the consideration required to be paid
by the Company may consist of cash equal to the fair market value of such property, as determined in good faith by the Board of Directors of the Company. 

        (b)    Sale of Shares to Offeror.    The Employee may, for 60 days after the expiration of the
30-day option period as set forth in Section 15(a), sell to the Offeror, pursuant to the terms of the Offer, all of such Offered Shares not purchased or agreed to be purchased by
the Company or its assignee; provided, however, that the Employee shall not sell such Shares to such Offeror if such 

Offeror
is a competitor of the Company and the Company gives written notice to the Employee, within 30 days of its receipt of the Option Notice, stating that the Employee shall not sell his or
her Shares to such Offeror; and provided, further, that prior to the sale of such Shares to an Offeror, such Offeror shall execute an agreement with the
Company pursuant to which such Offeror agrees to be subject to the restrictions set forth in this Section 15. If any or all of such Shares are not sold pursuant to an Offer within the time
permitted above, the unsold Shares shall remain subject to the terms of this Section 15. 

        (c)    Failure to Deliver Shares.    If the Employee (or his or her legal representative) who has become obligated to
sell Shares hereunder shall fail to deliver such shares to the Company in accordance with the terms of this agreement, the Company may, at its option, in addition to all other remedies it may have,
mail to the Employee the purchase price for such shares as is herein specified. Thereupon, the Company: (i) shall cancel on its books the certificate or certificates representing such Shares to
be sold; and (ii) shall issue, in lieu thereof, a new certificate or certificates in the name of the Company representing such Shares (or cancel such Shares), and thereupon all of such
Employee's rights in and to such Shares shall terminate. 

        (d)    Expiration of Company's Right of First Refusal and Transfer Restrictions.    The first refusal rights of the
Company and the transfer restrictions set forth in this Section 15 shall expire as to Shares on the earliest to occur of (i) the tenth anniversary of the date of this agreement or
(ii) immediately prior to the closing of a public offering of Common Stock by the Company pursuant to an effective registration statement filed under the Securities Act. In addition, if the
Company and the Employee are parties to an agreement containing first refusal provisions similar to the foregoing, such other agreement shall control. 

        16.    Early Disposition.    The Employee agrees to notify the Company in writing immediately after the Employee
transfers any Shares, if such transfer occurs on or before the later of (a) the date that is two years after the date of this agreement or (b) the date that is one year after the date on
which the Employee acquired such Shares. The Employee also agrees to provide the Company with any information concerning any such transfer required by the Company for tax purposes. 

        17.    Lock-up Agreement.    The Employee agrees that in the event that the Company effects an initial
underwritten public offering of Common Stock registered under the Securities Act, the Shares may not be sold, offered for sale or otherwise disposed of, directly or indirectly, without the prior
written consent of the managing underwriter(s) of the offering, for such period of time after the execution of an underwriting agreement in connection with such offering that all of the Company's then
directors and executive officers agree to be similarly bound. 

        18.    Arbitration.    Any dispute, controversy, or claim arising out of, in connection with, or relating to the
performance of this agreement or its termination shall be settled by arbitration in the Commonwealth of Massachusetts, pursuant to the rules then obtaining of the American Arbitration Association. Any
award shall be final, binding and conclusive upon the parties and a judgment rendered thereon may be entered in any court having jurisdiction thereof. 

        19.    Provision of Documentation to Employee.    By signing this agreement the Employee acknowledges receipt of a
copy of this agreement and a copy of the Plan. 

        20.    Miscellaneous.    

        (a)    Notices.    All notices hereunder shall be in writing and shall be deemed given when sent by mail, if to the
Employee, to the address set forth below or at the address shown on the records of the Company, and if to the Company, to the Company's principal executive offices, attention of the Corporate
Secretary. 

        (b)    Entire Agreement; Modification.    This agreement constitutes the entire agreement between the parties relative
to the subject matter hereof, and supersedes all proposals, written or oral, and all other communications between the parties relating to the subject matter of this 

agreement.
This agreement may be modified, amended or rescinded only by a written agreement executed by both parties. 

        (c)    Fractional Shares.    If this option becomes exercisable for a fraction of a share because of the adjustment
provisions contained in the Plan, such fraction shall be rounded down. 

        (d)    Issuances of Securities; Changes in Capital Structure.    Except as expressly provided herein or in the Plan,
no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect
to, the number or price of shares subject to this option. No adjustments need be made for dividends paid in cash or in property other than securities of the Company. If there shall be any change in
the Common Stock of the Company through merger, consolidation, reorganization, recapitalization, stock dividend, stock split, combination or exchange of shares, spin-off,
split-up or other similar change in capitalization or event, the restrictions contained in this agreement shall apply with equal force to additional and/or substitute securities, if any,
received by the Employee in exchange for, or by virtue of his or her ownership of, Shares, except as otherwise determined by the Board. 

        (e)    Severability.    The invalidity, illegality or unenforceability of any provision of this agreement shall in no
way affect the validity, legality or enforceability of any other provision. 

        (f)    Successors and Assigns.    This agreement shall be binding upon and inure to the benefit of the parties hereto
and their respective successors and assigns, subject to the limitations set forth in Section 10 hereof. 

        (g)    Governing Law.    This agreement shall be governed by and interpreted in accordance with the laws of the
Commonwealth of Massachusetts, without giving effect to the principles of the conflicts of laws thereof. 

HELICOS BIOSCIENCES CORPORATION 

RESTRICTED STOCK PURCHASE AGREEMENT  

        Helicos BioSciences Corporation (the "Company") hereby issues and sells the shares of its common stock specified
below (the "Shares") pursuant to its 2003 Stock Option and Incentive Plan. The terms and conditions attached hereto are also a part hereof. 

	

Name of purchaser (the "Stockholder"):	
 	

 
	

Date:	
 	

 
	

Number of shares sold hereunder (the "Shares"):	
 	

 
	

Purchase price per share:	
 	

 
	

Number of Shares that are Vested Shares on the Vesting Start Date:	
 	

 
	

Number of Shares that are Unvested Shares on the Vesting Start Date:	
 	

 
	

Vesting Start Date:	
 	

 
	
Vesting Schedule:	
 	

 
	

One year from the Vesting Start Date	
 	

25% of the Shares
	

The first business day of each month following the first anniversary of the Vesting Start Date:	
 	

An additional 2.0833333% of the Shares
	

All vesting is dependent on the continuation of a Business Relationship with the Company, as provided herein.

        This
stock purchase satisfies in full all commitments that the Company has to the Stockholder with respect to the issuance of stock, stock options or other equity securities. 

	

 	
 	

HELICOS BIOSCIENCES CORPORATION
	    
	 	 	 
	Signature of Stockholder	 	By:	    

	    
 Street Address	 	 	Name of Officer:

Title:
	    
 City/State/Zip Code	 	 	 

HELICOS BIOSCIENCES CORPORATION
 RESTRICTED STOCK PURCHASE AGREEMENT—INCORPORATED TERMS AND CONDITIONS  

        Helicos BioSciences Corporation (the "Company") agrees to sell to the Stockholder, and the Stockholder agrees to
purchase from the Company, shares of the Company's common stock ("Common Stock") on the following terms and conditions: 

        1.    Grant Under Plan.    This stock purchase is made pursuant to and is governed by the Company's 2003 Stock Option
and Incentive Plan (the "Plan") and, unless the context otherwise requires, terms used herein shall have the same meanings as in the Plan. The
Stockholder acknowledges receipt of a copy of the Plan. 

        2.    Purchase and Sale of Stock; Payment of Purchase Price.    The Company hereby sells and the Stockholder hereby
purchases the Shares specified on the cover page at the price specified thereon. The purchase price is being paid by the Stockholder upon execution and delivery of this agreement as set forth on the
cover page hereof. The Company will promptly issue a certificate or certificates registered in the
Stockholder's name representing the Shares, with such certificates to be held in escrow in accordance with the terms hereof. 

        3.    Vesting if Business Relationship Continues.    

        (a)    Vesting Schedule.    If the Stockholder has continuously maintained a Business Relationship with the Company
through the vesting dates specified on the cover page hereof, Unvested Shares shall become Vested Shares (or shall "vest") on such dates in an amount
equal to the number of shares set opposite the applicable date on the cover page. "Unvested Shares" shall be subject to the repurchase provisions
described in Section 4 unless and until they become "Vested Shares." The Stockholder agrees not to sell, assign, transfer, pledge, hypothecate,
gift, mortgage or otherwise encumber or dispose of (except to the Company or any successor to the Company) all or any Unvested Shares or any interest therein, and any Unvested Shares shall be held in
escrow by the Company in accordance with the terms of Section 6 below unless and until they become Vested Shares. Unless otherwise specified herein, if the Stockholder's Business Relationship
with the Company ceases, voluntarily or involuntarily, with or without cause, no Unvested Shares shall become Vested Shares thereafter under any circumstances with respect to the Stockholder. Any
determination under this agreement as to the status of a Business Relationship or other matters referred to above shall be made in good faith by the Board of Directors of the Company. The Board of
Directors, in its discretion, may accelerate any vesting dates. 

        (b)    Definitions.    The following definitions shall apply: 

        "Business Relationship" means service to the Company or its successor in the capacity of an employee, officer, director or consultant. 

        "Cause" means: (i) a breach of fiduciary or confidentiality obligations to the Company by you or (ii) conviction of
criminal misconduct by you in connection with the performance of your duties as an employee and officer of the Company. 

        (c)    Termination of Employment.    For purposes hereof, employment shall not be considered as having terminated
during any leave of absence if such leave of absence has been approved in writing by the Company and if such written approval contractually obligates the Company to continue the employment of the
Stockholder after the approved period of absence; in the event of such an approved leave of absence, vesting of Unvested Shares shall be suspended (and the period of the leave of absence shall be
added to all vesting dates) unless otherwise provided in the Company's written approval of the leave of absence. This agreement shall not be affected by any change of employment within or among the
Company and its Subsidiaries so long as the Stockholder continuously remains an employee of the Company or any Subsidiary. 

        4.    Restrictions on Transfer; Purchase by the Company.    The Stockholder may not sell, assign, transfer, pledge,
encumber or dispose of ("Transfer") all or any of his or her Unvested Shares except to the Company pursuant to this Section 4, and may Transfer
Vested Shares only in accordance with the 

transfer
restrictions provided in this Section 4 or elsewhere in this agreement. The Stockholder may not at any time transfer any Shares to any individual, corporation, partnership or other
entity that engages in any business activity that is in competition, directly or indirectly, with the products or services being developed, manufactured or sold by the Company. The determination of
whether any proposed transferee engages in any business activity that is in competition with those of the Company shall be made by the Board of Directors of the Company in good faith. This prohibition
shall be applicable in addition to and separately from the other provisions hereof. 

        Upon
the termination of the Stockholder's Business Relationship, the Stockholder shall sell to the Company (or the Company's assignee) all Unvested Shares in accordance with the
procedures set forth below. The purchase price (the "Repurchase Price") of such Shares (the "Repurchased
Shares") shall be the price paid for them (subject to adjustment as herein provided). The sale of the Repurchased Shares shall take place automatically upon termination of the
Stockholder's Business Relationship. Such sale shall be effected by the Escrow Holder's (as defined below) delivery to the Company of a certificate or certificates evidencing the Repurchased Shares,
duly endorsed for transfer to the Company. Upon receipt thereof, the Company shall mail a check for the Repurchase Price to the Stockholder or shall cancel indebtedness owed to the Company by the
Stockholder by written notice mailed to the Stockholder, or both. Upon the mailing of a check in payment of the purchase price in accordance with the terms hereof or cancellation of indebtedness as
aforesaid, the Company shall become the legal and beneficial owner of the Shares being repurchased and all rights and interests therein or relating thereto, and the Company shall have the right to
retain and transfer to its own name or cancel the number of Shares being repurchased by the Company. 

        Notwithstanding
the foregoing and the provisions of Section 8, a Stockholder may transfer: (i) all or any Vested Shares as a gift to any family member or to any trust or
similar estate planning entity for the benefit of any such family member or the Stockholder provided that any such transferee shall agree in writing
with the Company, as a condition precedent to such transfer, to be bound by all of the provisions of this agreement to the same extent as if such transferee were the Stockholder, or (ii) any or
all Vested Shares by will or the laws of descent and distribution, in which event each such transferee shall be bound by all of the provisions of this agreement to the same extent as if such
transferee were the Stockholder or (iii) any or all Vested or Unvested Shares by court order, in which event each such transferee shall be bound by all of the provisions of this agreement to
the same extent as if such transferee were the Stockholder. As used herein, the word "family" shall include any spouse, lineal ancestor or descendant
(whether natural or adoptive), brother or sister of the Stockholder. 

        5.    Investment Representation.    The Stockholder represents, warrants and acknowledges that the Stockholder:
(i) has had an opportunity to ask questions of and receive answers from a Company representative concerning the terms and conditions of this investment; (ii) is acquiring the Shares with
the Stockholder's own funds, for the Stockholder's own account for the purpose of investment, and not with a view to any resale or other distribution thereof in violation of the Securities Act of
1933, as
amended (the "Securities Act"); (iii) is a sophisticated investor with such knowledge and experience in financial and business matters as to be
able to evaluate the merits and risks of an investment in the Shares and that the Stockholder is able to and must bear the economic risk of the investment in the Shares for an indefinite period of
time because the Shares have not been registered under the Securities Act, and therefore, cannot be offered or sold unless they are subsequently registered under the Securities Act or an exemption
from such registration is available. Furthermore, the Company may place legends on any stock certificate representing the Shares with the securities laws and contractual restrictions thereon and issue
related stop transfer instructions. 

        The
Stockholder acknowledges and understands that the Shares have not been registered under the Securities Act, nor registered pursuant to the provisions of the securities laws or other
laws of any other applicable jurisdictions, in reliance on exemptions for private offerings contained in Section 4(2) of the Securities Act and in the laws of such jurisdictions. The
Stockholder further understands that the Company has no intention and is under no obligation to register the Shares under the Securities Act or to comply with the requirements for any exemption that
might otherwise be available, or to supply the 

Stockholder
with any information necessary to enable the Stockholder to make routine sales of the Shares under Rule 144 or any other rule of the Securities and Exchange Commission. 

        6.    Escrow of Shares.    All Shares shall be held in escrow until payment in full of the note (if any) referred to
on the cover page and thereafter all Unvested Shares shall be held in escrow by the Company, as escrow holder ("Escrow Holder"). 

        The
Escrow Holder is hereby directed to transfer the Unvested Shares in accordance with this agreement or instructions signed by both the Stockholder and the Company. If the Company or
any assignee exercises its repurchase rights hereunder, the Escrow Holder, upon receipt of written notice of such exercise from the Company or such assignee, shall take all steps necessary to
accomplish such transfer. The Stockholder hereby grants the Escrow Holder an irrevocable power of attorney coupled with an interest to take any and all actions required to effect such transfer. 

        The
Escrow Holder may act in reliance upon advice of counsel in reference to any matter(s) connected with this agreement, and shall not be liable for any mistake of fact or error of
judgment, or for any acts or omissions of any kind, unless caused by its willful misconduct or gross negligence. 

        With
respect to any Unvested Shares that become Vested Shares, the Company, upon the written request of the Stockholder, shall promptly issue a new certificate for the number of shares
which have become Vested Shares and shall deliver such certificate to the Stockholder and shall deliver to the Escrow Holder a new certificate for the remaining Unvested Shares in exchange for the
certificate then being held by the Escrow Holder. 

        Subject
to the terms hereof, the Stockholder shall have all the rights of a stockholder with respect to the Unvested Shares while they are held in escrow, including without limitation,
the right to vote the Unvested Shares and receive any cash dividends declared thereon. If, from time to time while the Escrow Holder is holding Unvested Shares, there is any stock dividend, stock
split or other change in or respecting such shares, any and all new, substituted or additional securities to which the Stockholder is entitled by reason of his or her ownership of the Unvested Shares
shall be immediately subject to this escrow, deposited with the Escrow Holder and included thereafter as "Unvested Shares" for purposes of this agreement and the repurchase rights of the Company. 

        7.    Certain Tax Matters.    If the Company in its discretion determines that it is obligated to withhold any tax in
connection with the transfer of, or the lapse of restrictions on, the Shares, the Stockholder hereby agrees that the Company may withhold from the Stockholder's wages or other remuneration the
appropriate amount of tax. At the discretion of the Company, the amount required to be withheld may be withheld in cash from such wages or other remuneration. The Stockholder further agrees that, if
the Company does not withhold an amount from the Stockholder's wages or other remuneration sufficient to satisfy the withholding obligation of the Company, the Stockholder will make reimbursement on
demand, in cash, for the amount underwithheld. 

        The
Stockholder represents that he or she has received tax advice from his or her own personal tax advisor on the tax consequences of a purchase of the Shares. The Stockholder
understands the tax consequences of filing (and not filing) a Section 83(b) election under the Internal Revenue Code of 1986, as amended (the
"Code"). The filing of a Section 83(b) election is the Stockholder's responsibility. 

        8.    Restrictions on Transfer of Vested Shares; Company's Right of First Refusal.    

        (a)    Exercise of Right.    Vested Shares may not be transferred without the Company's written consent except in
accordance with Section 4 or in accordance with the further provisions of this Section 8. If the Stockholder desires to transfer all or any part of the Vested Shares to any person other
than the Company (an "Offeror"), the Stockholder shall: (i) obtain in writing an irrevocable and unconditional bona
fide offer (the "Offer") for the purchase thereof from the Offeror; and (ii) give written notice (the
"Option Notice") to the Company setting forth the Stockholder's desire to transfer such shares, which Option Notice shall be accompanied by a photocopy
of the Offer and shall set forth at least the name and address of the Offeror and the price, number of Vested 

Shares
proposed to be sold and terms of the Offer. Upon receipt of the Option Notice, the Company shall have an assignable option to purchase all but not less than all of such Vested Shares (the
"Offered Shares") specified in the Option Notice, such option to be exercisable by giving, within 30 days after receipt of the Option Notice, a
written counter-notice to the Stockholder. If the Company elects to purchase such Offered Shares, it shall be obligated to purchase, and the Stockholder shall be obligated to sell to the Company or
its assignee, such Offered Shares at the price and terms indicated in the Offer within 30 days from the date of delivery by the Company of such counter-notice. To the extent that the
consideration proposed to be paid by the Offeror for the shares consists of property other than cash or a promissory note, the consideration required to be paid by the Company may consist of cash
equal to the fair market value of such property, as determined in good faith by the Board of Directors of the Company. 

        (b)    Sale of Vested Shares to Offeror.    The Stockholder may, for 60 days after the expiration of the option
period as set forth in Section 8(a), sell to the Offeror, pursuant to the terms of the Offer, all of the Offered Shares not purchased or agreed to be purchased by the Company or its assignee;  provided, however,
 that the Stockholder shall not sell such Shares to such Offeror if such Offeror is a competitor of the Company and the Company gives
written notice to the Stockholder, within 30 days of its receipt of the Option Notice, stating that the Stockholder shall not sell his or her Vested Shares to such Offeror; and  provided, further,
that prior to the sale of such Vested Shares to an Offeror, such Offeror shall execute an agreement with the Company pursuant to
which such Offeror agrees to be subject to the restrictions set forth in this Section 8. If any or all of such Vested Shares are not sold pursuant to an Offer within the time permitted above,
the unsold Vested Shares shall remain subject to the terms of this Section 8. 

        (c)    Expiration of Company's Right of First Refusal and Transfer Restrictions.    The first refusal rights of the
Company and the transfer restrictions set forth in this Section 8 shall expire as to Vested Shares on the earliest to occur of (i) the tenth anniversary of the date of this agreement,
(ii) immediately prior to the closing of a public offering of Common Stock by the Company pursuant to an effective registration statement filed under the Securities Act, or (iii) the
occurrence of an Acquisition that is not a Private Transaction. In addition, if the Company and the Stockholder are parties to an agreement containing first refusal provisions similar to the
foregoing, such other agreement shall control. For the purposes of this paragraph, the term Private Transaction shall mean any Acquisition where the consideration received or retained by the holders
of the then outstanding capital stock of the Company does not consist of (i) cash or cash equivalent consideration, (ii) securities which are registered under the Securities Act and/or
(iii) securities for which the Company or any other issuer thereof has agreed, including pursuant to a demand, to file a registration statement within ninety (90) days of
completion of the transaction for resale to the public pursuant to the Securities Act. 

        9.    Failure to Deliver Shares.    If the Stockholder (or his or her legal representative) who has become obligated
to sell Shares hereunder shall fail to deliver such Shares to the Company in accordance with the terms of this agreement, the Company may, at its option, in addition to all other remedies it may have,
mail to the Stockholder the purchase price for such Shares as is herein specified. Thereupon, the Company: (i) shall cancel on its books the certificate or certificates representing such Shares
to be sold; and (ii) shall issue, in lieu thereof, a new certificate or certificates in the name of the Company representing such Shares (or cancel such Shares), and thereupon all of such
Stockholder's rights in and to such Shares shall terminate. 

        10.    Lock-up Agreement.    The Stockholder agrees that in the event that the Company effects an initial
underwritten public offering of Common Stock registered under the Securities Act, the Shares may not be sold, offered for sale or otherwise disposed of, directly or indirectly, without the prior
written consent of the managing underwriter(s) of the offering, for such period of time after the execution of an underwriting agreement in connection with such offering that all of the Company's then
directors and executive officers agree to be similarly bound. 

        11.    Arbitration.    Any dispute, controversy, or claim arising out of, in connection with, or relating to the
performance of this agreement or its termination shall be settled by arbitration in Massachusetts pursuant to the rules then obtaining of the American Arbitration Association. Any award shall be
final, binding and conclusive upon the parties and a judgment rendered thereon may be entered in any court having jurisdiction thereof. 

        12.    Provision of Documentation to Stockholder.    By signing this agreement the Stockholder acknowledges receipt of
a copy of this agreement and a copy of the Plan. 

        13.    Miscellaneous.    

        (a)    Notices.    All notices hereunder shall be in writing and shall be deemed given when sent by mail, if to the
Stockholder, to the address set forth below or at the address shown on the records of the Company, and if to the Company, to the Company's principal executive offices, attention of the Corporate
Secretary. 

        (b)    Entire Agreement; Modification.    This agreement constitutes the entire agreement between the parties relative
to the subject matter hereof, and supersedes all proposals, written or oral, and all other
communications between the parties relating to the subject matter of this agreement. This agreement may be modified, amended or rescinded only by a written agreement executed by both parties. 

        (c)    Fractional Shares.    All fractional Shares resulting from the adjustment provisions contained in the Plan
shall be rounded down. 

        (d)    Changes in Capital Structure.    In the event of any stock split, stock dividend, recapitalization,
reorganization, merger, consolidation, combination, exchange of shares, liquidation, spin-off, split-up, or other similar change in capitalization or event, the securities
received in respect of such event shall be "Shares" hereunder subject to this agreement and shall retain the same status as "Vested Shares" or "Unvested Shares" as the Shares in respect of which they
were received, and the repurchase price per security subject to repurchase shall be appropriately adjusted by the Company. 

        (e)    Severability.    The invalidity, illegality or unenforceability of any provision of this agreement shall in no
way affect the validity, legality or enforceability of any other provision. 

        (f)    Successors and Assigns.    This agreement shall be binding upon and inure to the benefit of the parties hereto
and their respective successors and assigns, subject to the limitations set forth herein. 

        (g)    Governing Law.    This agreement shall be governed by and interpreted in accordance with the laws of
Massachusetts without giving effect to the principles of the conflicts of laws thereof. 

        (h)    No Obligation to Continue Employment.    Neither the Plan, this agreement nor any provision hereof imposes any
obligation on the Company to continue the Stockholder in employment or any other Business Relationship with the Company. 

QuickLinks

Exhibit 10.6

HELICOS BIOSCIENCES CORPORATION

HELICOS BIOSCIENCES CORPORATION NON-QUALIFIED STOCK OPTION AGREEMENT—INCORPORATED TERMS AND CONDITIONSQuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.7    
    

 
 

LICENSE AGREEMENT    
    

        THIS AGREEMENT is effective as of
the                        day
of                        , 2003 (the
"Effective Date"), between CALIFORNIA INSTITUTE OF TECHNOLOGY, 1200 East California Boulevard, Pasadena,
CA 91125 ("Caltech") and Helicos BioSciences Corp. ("Licensee"), a corporation having a place of
business at 150 CambridgePark Drive, Cambridge, MA 02140. 

        WHEREAS, Licensee is desirous of obtaining, and Caltech wishes to grant to Licensee, an exclusive license to certain Exclusively Licensed
Patent Rights and to the Improvement Patent Rights, and a nonexclusive license under the Technology, all relating to the aforementioned research and as further defined below; 

        NOW, THEREFORE, the parties agree as follows: 

 
 

ARTICLE 1
  DEFINITIONS    
    

        1.1   "Affiliate" means any corporation, limited liability company or other legal entity which directly or indirectly controls,
is controlled by, or is under common control with Licensee. For the purpose of this Agreement, "control" shall mean the direct or indirect ownership of at least fifty-one percent (51%) of
the outstanding shares on a fully diluted basis or other voting rights of the subject entity to elect directors, or if not meeting the preceding, any entity owned or controlled by or owning or
controlling at the maximum control or ownership right permitted in the country where such entity exists. In addition, a party's status as an Affiliate of License shall terminate if and when such
control ceases to exist. 

        1.2   "Technology" means any Technology, meeting any of the following criteria: (a) such Technology is specifically
listed in Exhibit B; (b) such Technology is directed to and specifically useful for the development of Licensed Products or Services; and (c) such Technology, in at least some
implementations, is not covered by any claim of the Exclusively Licensed Patent Rights. Technology includes all proprietary information, know-how, procedures, methods, prototypes, designs
existing as of the Effective Date or thereafter developed for a period of three (3) years from the Effective Date of the Agreement, unless otherwise extended by agreement of the Parties. 

        1.3   "Caltech Technology" means the Exclusively Licensed Patent Rights, Improvement Patent Rights, and the Technology. 

        1.4   "Deductible Expenses" means the following expenses incurred in connection with sales or licensing of Licensed Products to
the extent actually paid by Licensee or an Affiliate in accordance with generally recognized principles of accounting: (a) sales, use or turnover taxes; (b) excise, value added or other,
taxes or custom duties; (c) transportation, freight, and handling charges, and insurance on shipments to customers; (d) trade, cash or quantity discounts or rebates to the extent
actually granted; (e) agent fees or commissions; and (f) rebates, refunds, and credits for any rejected or returned Licensed Products or because of retroactive price reductions, rebates
or chargebacks. 

        1.5   "Effective Date" has the meaning set forth in the preamble. 

        1.6   "Exclusively Licensed Patent Rights" means Caltech's rights under: (a) all patents and patent applications listed
in Exhibit A attached hereto and Improvement Patent Rights thereof; (b) any patents issuing therefrom; and (c) any patents or patent applications claiming a right of priority
thereto (including reissues, reexaminations, renewals, extensions, divisionals, continuations, continued prosecution applications, continuations-in-part and foreign
counterparts of any of the foregoing). 

1

 

        1.7   "Field" means all fields. 

        1.8   "Improvement Patent Rights" means Caltech's rights under: (a) all patents and patent applications with claims
directed to Improvements; (b) any patents issuing therefrom; and (c) any patents or patent applications claiming a right of priority thereto (including reissues, reexaminations,
renewals, extensions, divisionals, continuations, continued prosecution applications, continuations-in-part and foreign counterparts of any of the foregoing). 

        1.9   "Improvements" means any future invention conceived and reduced to practice or otherwise developed in the laboratory of
Profs. Stephen Quake or Brian Stoltz at Caltech, either solely or jointly with Licensee in the Field, for a period of three (3) years from the Effective Date (the "Improvements Period") and
which are dominated by a Valid Claimor which embody the Caltech Technology. The parties agree to negotiate in good faith, at the request of the Licensee, prior to the expiration of the Improvements
Period to extend the Improvements Period to no less than five (5) years from the Effective Date. 

        1.10 "Internal Projects" means internal research and development projects
utilizing Licensed Products for the purpose of generating licensable intellectual property such as biological data and content, targets, biomarkers, mechanisms of disease and the like. 

        1.11 "Licensed Product" means any physical product or device, in the Field, that is covered by, or is made by a process
covered by, any Valid Claim of the Exclusively Licensed Patent Rights or a Valid Claim of Improvement Patent Rights or that utilizes Technology in material part. 

        1.12 "Service" means any service other than maintenance and repair services, technical application development, field support
or the like, in the Field that is covered by, or is made by a process covered by, any Valid Claim of the Exclusively Licensed Patent Rights or a Valid Claim of Improvement Patent Rights or that
utilizes Technology in material part. 

        1.13 "Net Product Revenues" means all amounts received by Licensee and/or its Affiliates from the sale, licensing, or other
distribution (whether commercial or not) to other parties of Licensed Products, less Deductible Expenses. Net Product Revenues shall exclude (i) sales to the United States Government,
(ii) Licensed Products used by Licensee in connection with Internal Projects and the performance of Services, and (iii) purchases of Licensed Products from third-parties for
re-distribution or use by Licensee or a Product Sublicensee. 

        1.14 "Other Developments" means any invention conceived and reduced to practice or otherwise developed in the laboratory of
Profs. Stephen Quake or Brian Stoltz at Caltech, either solely or jointly with Licensee in the Field (including, but not limited to, related proprietary information, patent rights,
know-how, procedures, methods, prototypes and designs), but which are not included in Exclusively Licensed Patent Rights or Improvement Patent Rights, to the extent such inventions are
owned and controlled by Caltech. 

        1.15 "Product Liability Claims" has the meaning set forth in Section 13.1 

        1.16 "Valid Claim" means: (a) a claim of an issued patent within the Exclusively Licensed Patent Rights that has not
(i) expired or been canceled, (ii) been finally adjudicated to be invalid or unenforceable by a decision of a court or other appropriate body of competent jurisdiction (and from which no
appeal is or can be taken), (iii) been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (iv) been abandoned in accordance with or as permitted by the
terms of this Agreement or by mutual written agreement; or (b) a claim included in a pending patent application within the Exclusively Licensed Patent Rights which claim is being actively
prosecuted in accordance with this Agreement and which has not been (i) canceled, (ii) withdrawn from consideration, (iii) finally determined to be unallowable by the applicable
governmental authority (and from which no appeal is or can be taken), or (iv) abandoned in accordance with or as permitted by the terms of this Agreement 

2

 

or
by mutual written agreement. Pending claims of the Exclusively Licensed Patent Rights shall be considered Valid Claims for five (5) years from the date of this Agreement. 

 
 

ARTICLE 2
  LICENSE GRANT    
    

        2.1    Grant of Rights.    Caltech hereby grants to Licensee the following licenses: 

        (a)   an
exclusive, royalty-bearing license under the Exclusively Licensed Patent Rights and Improvements under the Improvement Patent Rights to make, have made, import, use,
distribute, have used, sell, have sold, and offer or have offered for sale Licensed Products and Services in the Field throughout the world; and 

        (b)   a
nonexclusive, perpetual, royalty-bearing license under the Technology to make, have made, import, use, sell, offer for sale, reproduce, distribute, display, perform,
create derivative works of, and otherwise exploit Licensed Products and Services in the Field throughout the world. 

        These
licenses are personal to and nontransferable by Licensee, except as provided in Section 2.3 and 14.9. 

        2.2    Reservation of Rights; Government Rights.    These licenses are subject to any existing right of the U.S.
Government under Title 35, United States Code, Section 200 et seq. and under 37 Code of Federal Regulations, Section 401 et seq., including but not limited to the grant to the U.S.
Government of a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced any invention conceived or first actually reduced to practice in the performance
of work for or on behalf of the U.S. Government throughout the world. 

        Licensee
agrees that all Licensed Products covered by an Exclusively Licensed Patent Right, and to be sold, licensed, distributed or used by or on behalf of Licensee or its Affiliates in
the United States, shall be manufactured substantially in the United States to the extent (if at all) required by 35 U.S.C. Section 204. 

        Rights
not explicitly granted herein are reserved by Licensor. 

        2.3    Sublicensing.    Licensee shall have the right to grant sublicenses to third parties to enable such third
parties to make, have made, import, use have used, sell have sold, and offer or have offered for sale Licensed Products (a "Product Sublicense", a licensee thereof being called a "Product Licensee.") 

        Such
sublicenses may be of no greater scope than the licenses under Sections 2.1 and 2.2. A holder of a Product Sublicense may transfer or further sublicense its sublicense in connection
with the sale of Licensed Products, provided the value of such transfer or further sublicense shall be included in the determination of Net Revenue. 

        Licensee
shall include all its sublicensing income in Licensee's reports to Caltech, as provided in Paragraph 5.11, and Licensee shall pay royalties thereon pursuant to
Article 5. 

        Licensee
shall not receive, or agree to receive, anything of value in lieu of cash or equity as Net Product Revenues from a third party under a sublicense granted pursuant to this
Paragraph 2.3, without Caltech's express prior written permission which shall not be unreasonably withheld. In such case, the non-cash Net Revenue received will be determined based
on the fair market value or a value mutually agreed upon. 

        Licensee
shall make available a true and complete copy of each sublicense and any changes or additions thereto upon the reasonable request of Caltech not more frequently than once per
year. 

        Any
sublicenses granted by Licensee shall survive termination of the licenses granted in Section 2.1, or of this Agreement, provided that the written agreement between Licensee
and 

3

 

sublicensee
pursuant to which the sublicense was granted (i) obligates the sublicensee to thereafter render to Caltech such royalties as would otherwise be due to Caltech by Licensee,
(ii) names Caltech as a third party beneficiary, and (iii) affirms that Licensee shall remain responsible for all obligations to sublicensee (other than those requiring Licensee to hold
a license under the Exclusively Licensed Patent Rights or Technology, unless Caltech (at its discretion) elects to assume such obligations. 

        2.4    No Other Rights Granted.    The parties agree that neither this Agreement, nor any action of the parties
related hereto, may be interpreted as conferring by implication, estoppel or otherwise, any license or rights under any intellectual property rights of Caltech other than as expressly and specifically
set forth in this Agreement, regardless of whether such other intellectual property rights are dominant or subordinate to the Exclusively Licensed Patent Rights. 

        2.5    Preferential Purchaser Status.    Caltech shall be entitled to purchase Licensed Products and Services from
Licensee for educational, research or other noncommercial purposes on pricing terms that are at least as favorable as any commercial pricing made available by Licensee to any third party. Caltech
shall accept other terms of such sales. 

 
 

ARTICLE 3
  DISCLOSURE AND DELIVERY    
    

        3.1    Exclusively Licensed Patent Rights.    On or before the one month anniversary of the Effective Date, Caltech
shall promptly disclose and deliver to Licensee copies of all patent applications and/or issued patents within the Exclusively Licensed Patent Rights, including all patent office correspondence
related thereto. 

        3.2    Tangible Embodiments.    On or before the one month anniversary of the Effective Date, Caltech shall promptly
disclose and deliver to Licensee any tangible embodiments as of the Effective Date of: (a) the inventions covered by the Exclusively Licensed Patent Rights; and (b) the Technology. Such
disclosure and delivery may occur in writing, orally, and/or in other tangible or intangible form, as appropriate to the subject matter thereof. 

        3.3    Improvements.    Caltech will make good faith efforts to convey to Licensee all disclosures relating to
Improvements within thirty (30) days of receipt of disclosure by Caltech. 

        3.4    Other Developments.    To provide Licensee with the opportunity to seek further licenses if so desired, Caltech
will, for five (5) years from the Effective Date of this Agreement, convey to Licensee disclosures relating to Other Developments, and will grant Licensee a three month
non-exclusive option to negotiate a license under patent applications claiming such inventions. Caltech will make good faith efforts to convey disclosures to Licensee within thirty
(30) days of receipt of disclosure by Caltech. To prevent misunderstanding, the provision of such disclosures does not constitute an automatic or guaranteed license to practice such inventions,
and such disclosures shall be considered confidential information of Caltech. 

        3.5    Technology.    Caltech will enable Licensee to review the ongoing research and development being conducted in
the laboratory of Profs. Stephen Quake and Brian Stoltz at Caltech. The parties shall conduct periodic meetings, no less frequently than once per year, to review and discuss the Caltech Technology. 

 
 

ARTICLE 4
  PROSECUTION OF PATENT APPLICATIONS AND
  PAYMENT OF PATENT COSTS    
    

        4.1    Prosecution by Licensee.    Licensee shall be responsible for the preparation, filing, prosecution and
maintenance of any and all patent applications and patents included in Exclusively Licensed Patent Rights. Licensee shall use reasonable efforts, consistent with its normal practices, to:
(a) prosecute any 

4

 

and
all patent application(s) in connection with the Exclusively Licensed Patent Rights; and (b) file and prosecute patent claims covering Improvements licensed hereunder for which Licensee or
Caltech deems it beneficial to obtain additional coverage. Licensee shall consult with Caltech as to the preparation, filing, prosecution and maintenance of such patent applications and patents and
shall furnish to Caltech, or to counsel of Caltech's choice, copies of documents relevant to any such preparation, filing, prosecution or maintenance as further set forth in Section 4.2 below.
Licensee may determine which countries in which to file or maintain patent applications. With respect to filings pursuant to Paragraph (b) herein above, Caltech shall promptly disclose such
Improvements to Licensee and Licensee shall elect within ninety (90) days whether such Improvements shall be included within the Exclusively Licensed Patent Rights. Licensee will have no
obligation to prosecute patent applications that may constitute Improvements that are not elected by Licensee. Upon written election by Licensee, the parties will amend Exhibit A hereto to
include inventions within the Exclusively Licensed Patent Rights, in a timely manner. 

        4.2    Cooperation.    Caltech and Licensee shall cooperate fully in the preparation, filing, prosecution and
maintenance of the Exclusively Licensed Patent Rights, including, but not limited to executing all papers and instruments or requiring members of Caltech to execute such papers and instruments so as
to enable Licensee to apply for, to prosecute and to maintain patent applications and patents in Caltech's name in any country. Each party shall provide to the other prompt notice as to all matters
which come to its attention and which may affect the preparation, filing, prosecution or maintenance of any such patent applications or patents. With respect to the drafting of patent applications,
Licensee shall provide draft patent applications to Caltech (or at the direction of Caltech, Caltech's counsel) at least ten (10) days before filing or within one-third of the time
span between disclosure of an invention to Licensee and the date of intended filing, whichever is less. With respect to documents relating to the prosecution of patent applications, Licensee shall
promptly provide Caltech (or at the direction of Caltech, Caltech's counsel) with copies of patent office correspondence, and shall provide Caltech (or at the direction of Caltech, Caltech's counsel)
with drafts of responses to patent office correspondence at least seven (7) days before transmission of such responses to the relevant patent office. Caltech or Caltech's counsel shall provide
any comments on such applications or responses promptly and in sufficient time to allow Licensee to meet applicable filing requirements. 

        4.3    Prosecution by Caltech.    If Licensee declines to file, prosecute or maintain any patent application or patent
referred to in Section 4.1, then the right to file, prosecute or maintain any such patent application or patent shall revert back to Caltech at its sole cost. 

        4.4    Patent Costs.    Except as otherwise set forth in this Section 4.4, Licensee shall bear the cost of
preparation, filing, prosecution and maintenance of any and all patent applications and patents included in Exclusively Licensed Patent Rights. Licensee shall reimburse Caltech for all reasonable
expenses (including attorneys' fees) incurred by Caltech prior to the Effective Date of this Agreement, for the
filing, prosecution and maintenance, interference and/or reexamination proceedings, of the Exclusively Licensed Patent Rights. Such payment shall be due thirty (30) days following the closing
of the Licensee's preferred stock financing of at least $5 million provided that Licensee has received from Caltech an invoice covering such fees (including copies of invoices for legal fees
describing the legal services performed in reasonable detail); provided further, however, that to the extent that such costs were in connection with foreign patent costs, such amounts shall be
creditable against earned royalties due Caltech in the respective territory covered by the patent or patents that are foreign filed. To the extent that Licensee incurs costs in connection with foreign
patent filings after the Effective Date of this Agreement, such amounts shall be creditable against earned royalties due Caltech in the respective territory covered by the patent or patents that are
foreign filed. 

5

  

 
 

ARTICLE 5
  ROYALTIES    
    

        5.1    Timing and Computation.    All domestic royalties hereunder shall be computed on a semi annual calendar year
basis. Domestic royalties for each calendar year end payment shall be due and payable within one hundred twenty (120) days after the end of such calendar year. Domestic royalties for each
mid-year period shall be due and payable within sixty (60) days after the end of the mid-year period. 

        All
foreign royalties hereunder shall be computed on an annual calendar year basis. Foreign royalties for each calendar year shall be due and payable within one hundred twenty
(120) days after the end of such calendar year. 

        5.2    Valid Claims.    For any country in which the Exclusively Licensed Patent Rights includes a Valid Claim,
Licensee shall pay Caltech a royalty of (i) [***] of Net Product Revenues attributable to each Licensed Product made, sold, licensed, distributed or used, by Licensee or
its Affiliates, in such country and (ii) the lesser of (A) [***] of Net Product Revenues attributable to each Licensed Product made, sold, licensed, distributed
or used, pursuant to a Product Sublicense, in such country or (B) [***] of the amount received by Licensee from the holder of a Product Sublicense relating to the sale
by the holder of the Product Sublicense of Licensed Products. 

        5.3    Technology.    For any country in which the Exclusively Licensed Patent Rights do not include a Valid Claim,
Licensee shall pay Caltech a royalty of (i) [***] of Net Product Revenues for each Licensed Product made, sold, licensed, distributed or used, by or on behalf of
Licensee or its Affiliates and (ii) the lesser of (A) [***] of Net Product Revenues attributable to each Licensed Product made, sold, licensed, distributed or
used, pursuant to a Product Sublicense or (B) [***] of the amount received by Licensee from the holder of a Product Sublicense relating to the sale by the holder of the
Product Sublicense of Licensed Products. Notwithstanding the forgoing, no royalties shall be due under this Section 5.3 three years after the first commercial sale in any such country. 

        5.4    Bundled Products.    In the event that Licensed Products are sold, licensed, distributed or used in combination
with one or more other products or services which are not Licensed Products or Services, and the value of the Licensed Products is not discreetly identified as a separate component of the total
consideration, then the Net Product Revenues for such combination products will be calculated on a country-by-country basis as follows: 

        By
multiplying actual net sales (calculated on the basis as if they were Net Product Revenues) of such combination products by the fraction A/(A+B) where A is the average invoice price,
during the relevant period, of the Licensed Product when sold or licensed separately by Licensee or a Affiliate, and B is the average invoice price during such period of any other product(s) or
services in the combination when sold or licensed separately by Licensee or an Affiliate. If the products or services in such combination that are not Licensed Products have not been sold or licensed
separately by Licensee or a Affiliate in the relevant period, Net Product Revenues shall be calculated by multiplying actual net sales (calculated on a basis as if they were Net Product Revenues) of
such combination products by the fraction A/C where A is the average invoice price, during the last period, of the Licensed Product when sold or licensed separately and C is the average invoice price
of the combination product during such period. If the Licensed Product has not been sold or licensed separately by Licensee or a Affiliate in the last period, regardless whether the combination
product without the Licensed Product is sold or licensed separately, Net Product Revenues shall be calculated as in the immediately preceding sentence except that A shall be the total manufacturing
cost of Licensed Product and C shall be the total manufacturing cost of the combination. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

6

 

        5.5    Non-Product Royalties.    Licensee shall pay Caltech [***] of the amount
received by Licensee in connection with the provision of Services and the sale or license of intellectual property arising from Internal Projects ("Net Non-Product Revenues"). Net
Non-Product Revenues specifically shall not include payments made by a third party in consideration of: (a) equity or debt securities of Licensee; (b) to support research or
development activities to be undertaken by Licensee; (c) the achievement by Licensee of specified milestones or benchmarks relating to the development of Licensed Products or licensable
intellectual property; (d) pilot studies; (e) performance-based milestones (excluding milestones tied to sales or marketing performance, which shall be subject to the percentage-based
payments to Caltech); (f) the license or sublicense of any intellectual property other than Caltech Technology; (g) products other than Licensed Products; or (h) reimbursement for
patent or other expenses. 

        5.6    Minimum Annual Royalties.    A minimum annual royalty of ten thousand dollars ($10,000) is due Caltech on
October 1, 2005 and each anniversary thereof. Any royalties paid under Sections 5.2, 5.3, 5.4 and 5.5 for the one-year period preceding the date of payment of the minimum annual
royalty shall be creditable against the annual minimum. Caltech shall have the right to terminate this Agreement pursuant to Section 10.2 for failure to pay such minimum annual royalty. 

        5.7    Third Party Royalty Offset on Net Product Revenues.    If Licensee or an Affiliate is required to make any
payment (including, but not limited to, royalties or other license fees) to one or more third parties to obtain a patent license in the absence of which it could not legally make, import, use, sell,
or offer for sale Licensed Products in any country, and Licensee provides Caltech with reasonably satisfactory evidence of such third-party payments, such third-party payments shall be fully
creditable against royalties owed to Caltech under Sections 5.2, 5.3 and 5.4, provided that in no one year shall the aggregate of all such expenses be credited against more than
[***] of royalty payments to Caltech. Any greater amount of such expenses may be carried over and credited against royalties owed in future years, subject in every case to the
[***] for that year. 

        5.8    Third Party Royalty Offset on Non-Product Revenues.    If Licensee or an Affiliate is required to
make any payment (including, but not limited to, royalties or other license fees) to one or more third parties to obtain a patent license in the absence of which it could not legally make, import,
use, sell, or offer in connection with the provision of Services or performance of Internal Projects in any country, and Licensee provides Caltech with reasonably satisfactory evidence of such
third-party payments, such third-party payments shall be fully creditable against royalties owed to Caltech under Section 5.5 above, provided that in no one year shall the aggregate of all such
expenses be credited against more than [***] of such royalty payments to Caltech. Any greater amount of such expenses may be carried over and credited against such royalties
owed in future years, subject in every case to the [***] for that year. 

        5.9    Currency Conversion.    For the purpose of determining royalties payable under this Agreement, any royalties or
other revenues Licensee receives from sublicenses in currencies other than U.S. dollars and any Net Product Revenues or Net Non-Product Revenues denominated in currencies other than U.S.
dollars shall be converted into U.S. dollars based on the average noon buying rate of the Federal Reserve Bank of New York for the annual period for which such royalties are calculated. 

        5.10    Convenience of the Parties.    Caltech and Licensee acknowledge that each of the royalties set forth in this
Article 5 represents an integrated royalty established for the convenience of the parties in order to avoid the technical, legal and accounting complexities of analyzing and apportioning the
relative contributions of the various forms of patent, copyright, and/or trade secret rights licensed to, and the various forms of technical assistance (if any) provided to, Licensee in connection
with the Licensed Products, Services and Internal Projects. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

7

 

        5.10    Recordkeeping and Audits.    Licensee shall keep complete and accurate production and accounting records
relating to commercialization (including via sublicensing) of Licensed Products, Services and transfer of intellectual property in connection Internal Projects. Caltech shall be entitled to have an
independent CPA periodically audit such records, during Licensee's normal business hours, to determine Licensee's compliance with the provisions of this Article 5. Licensee shall reimburse
Caltech 100% of any unpaid royalties resulting from any noncompliance discovered as a result of any such audit; and Licensee shall also pay Caltech an additional 25% of the entire amount of any
underpayment exceeding 20% of the corresponding amount previously paid. Such audits shall be at Caltech's expense, and shall occur no more than once annually, except that in the case of any
underpayment exceeding 20% of the amount actually paid: (a) Licensee shall reimburse Caltech for the cost of such audit; and (b) Caltech shall be entitled to conduct additional annual
audits, at Licensee's expense, until any such audit demonstrates that Licensee is in compliance with its obligations. 

        5.11    Royalties
due under this Article 5 shall be payable on a country-by-country and Licensed Product-by-Licensed
Product basis until the expiration of the last-to-expire issued Valid Claim covering such Licensed Product in such country, or if no such patent has previously issued in a
country, until the fifth anniversary of the first commercial sale of Licensed Product in any country. 

        5.12    Notwithstanding
the provisions of this Article 5, no royalty shall be payable to Caltech with respect to any sales of Licensed Products on sales made solely to
permit the U.S. Government to practice or have practiced on its behalf any invention or process covered by Caltech Technology. 

        5.13    No
more than one royalty payment shall be due with respect to a sale of a particular Licensed Product or intellectual property licensed in connection with Services or
Internal Projects. No royalty shall be payable under this Article 5 with respect to Licensed Products distributed for use in research and/or development or as promotional samples or otherwise
distributed without charge to third parties. 

 
 

ARTICLE 6
  LICENSEE EQUITY INTEREST    
    

        6.1    Common Stock Grant.    At the closing of the Series A Financing, Licensee agrees to irrevocably issue to
Caltech, in partial consideration of Licensee's receipt of the licenses granted under this Agreement, such number of shares of common stock of the Licensee equal to $200,000 divided by the per share
purchase price paid for the Series A Preferred Stock, subject to the Licensee's standard equity agreement. 

        6.2    Transfer Restrictions.    Caltech agrees that, in the event of any underwritten or public offering of
securities of Licensee or an Affiliate, Caltech shall comply with and agree to any legally required restriction on the transfer of its equity interest, or any part thereof, imposed by the underwriter,
and shall perform all acts and sign all necessary documents required with respect thereto. 

 
 

ARTICLE 7
  DUE DILIGENCE    
    

        7.1    Commercialization.    Licensee agrees to use commercially reasonable efforts to commercially introduce Licensed
Product(s) or Services or perform Internal Projects in the Field as soon as practicable. Licensee shall be deemed to have satisfied its obligations under this Section 7.1 if Licensee has an
ongoing and active research, development or marketing program (as appropriate to the stage of development of the technology in question), directed primarily toward Internal Projects or the commercial
production and use of one or more Licensed Products or Services in a manner consistent with the normal business practices of other commercial entities (if any) who are active in the Field. Any efforts
of Licensee's Affiliates or sublicensees shall be considered efforts of Licensee for the sole purpose of determining Licensee's compliance with its obligation under this Section 7.1. 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

8

 

        7.2    Reporting.    Within one hundred and twenty (120) days after the end of each full calendar year during
the Term of this Agreement, Licensee shall issue to Caltech a detailed written report on its progress in performing Internal Projects, and introducing commercial Licensed Product(s) and Services. Such
report shall be considered confidential information of Licensee subject to Article 11. 

        7.3    Failure to Commercialize.    At any time after the second anniversary of the Effective Date of this Agreement,
Caltech may assert that if Licensee is not fulfilling its obligations under Section 7.1, provided Caltech so notifies Licensee in writing. Licensee shall have sixty (60) days to rebut
the assertion and Caltech and Licensee shall negotiate in good faith additional efforts, if any, to be taken by Licensee. If the parties do not reach agreement within ninety (90) days of
Caltech's written notice, the parties shall submit the issue to arbitration as provided in Article 12. 

 
 

ARTICLE 8
  LITIGATION    
    

        8.1    Enforcement.    Both Caltech and Licensee agree to promptly notify the other in writing should either party
become aware of possible infringement by a third party of the Exclusively Licensed Patent Rights in any part of the Field. Licensee may, upon notice to Caltech, initiate an action at Licensee's
expense, either in Licensee's name or in Caltech's name if so required by law. Licensee shall be entitled to control any such action initiated by it. If Licensee elects to commence such action,
Caltech may, to the extent permitted by law, elect to participate in that action through its own counsel at its own expense. 

        8.2    Other Defensive Litigation.    If a declaratory judgment action alleging invalidity, unenforceability or
noninfringement of any of the Exclusively Licensed Patent Rights is brought against Licensee and/or Caltech, Licensee may elect to control the defense of such action, and if Licensee so elects it
shall bear all the costs of the action. Licensee may also undertake the Caltech shall receive an amount equal to the past royalties it would have received if such sales had been made by Licensee,
provided such an amount shall in no event exceed thirty percent (30%) of the remainder; and 

        (b)   To
the extent the amount recovered does not reflect Licensee's lost profits or past royalties, seventy percent (70%) shall be paid to the party controlling the action at
the time of recovery, and thirty percent (30%) to the other party. 

        8.6    Infringement Defense.    If Licensee, its Affiliate or sublicensee, distributor or other customer is sued by a
third party charging infringement of patent rights that cover a Licensed Product, Licensee will promptly notify Caltech. Licensee, at its election, will be responsible for the expenses of, and will be
entitled to control the defense or settlement of, any such action(s). 

        8.7    Marking.    Licensee agrees to mark the Licensed Products with the numbers of applicable issued patents within
the Exclusively Licensed Patent Rights, unless such marking is commercially infeasible in accordance with normal commercial practices in the Field, in which case the parties shall cooperate to devise
a commercially reasonable alternative to such marking. 

        8.8    Expiration or Abandonment.    In a case where one or more patents or particular claims thereof within the
Exclusively Licensed Patent Rights expire, or are abandoned, or are declared invalid or unenforceable by a court of last resort or by a lower court from whose decree no appeal is taken, or certiorari
is not granted within the period allowed therefore, then the effect thereof hereunder shall be: 

        (a)   that
such patents or particular claims shall, as of the date of expiration or abandonment or final decision as the case may be, cease to be included within the Licensed
Patent Rights for the purpose of this Agreement; and 

        (b)   that
such construction so placed upon the Licensed Patent Rights by the court shall be followed from and after the date of entry of the decision, and royalties shall
thereafter be payable by Licensee only in accordance with such construction. 

9

  

        In the event that Licensee challenges the validity of Licensed Patent Rights, Licensee may not cease paying royalties as of the date validity of the claims in issue are challenged, but
rather may cease paying royalties as to those claims only after a final adjudication of invalidity of those claims. 

        8.9    Adjustment.    In the event that resolution of any actions under this Article 8 negatively effects the
Licensee's rights under the Exclusively Licensed Patent Rights, Caltech agrees to renegotiate in good faith with Licensee a reasonable royalty rate for the Exclusively Licensed Patent Rights which
Licensee desires to retain a License. 

 
 

ARTICLE 9
  REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION    
    

        9.1    Representations and Warranties of Caltech.    Caltech hereby represents and warrants to Licensee that as of the
Effective Date: 

        (a)   other
than rights granted to the US Government under United States statutes, there are no outstanding licenses, options or agreements of any kind relating to the
Exclusively Licensed Patent Rights, other than pursuant to this Agreement herein; 

        (b)   there
are no liens, mortgages, or encumbrances of any kind or any nature whatsoever against the Exclusively Licensed Patent Rights; and 

        (c)   Caltech
has the power to grant the rights, licenses and privileges granted herein and can perform as set forth in this Agreement without violating the terms of any
agreement that Caltech has with any third party. 

        9.2    Exclusions.    The parties agree that nothing in this Agreement shall be construed as, and CALTECH HEREBY
DISCLAIMS, ANY EXPRESS OR IMPLIED REPRESENTATION, WARRANTY, COVENANT, OR OTHER OBLIGATION: 

        (a)   THAT
ANY PRACTICE BY OR ON BEHALF OF LICENSEE OF ANY INTELLECTUAL PROPERTY LICENSED HEREUNDER IS OR WILL BE FREE FROM INFRINGEMENT OF RIGHTS OF THIRD PARTIES; 

        (b)   AS
TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF THIRD PARTY RIGHTS, WITH RESPECT TO ANY TECHNOLOGY PROVIDED BY CALTECH TO
LICENSEE HEREUNDER. 

        9.3    Indemnification by Caltech.    Caltech shall indemnify, defend and hold harmless Licensee from and against any
and all losses, damages, costs and expenses (including attorneys' fees) arising out of a material breach by Caltech of its representations and warranties ("Indemnification
Claims"), except to the extent involving or relating to a material breach by Licensee of its representations and warranties, provided that: (a) Caltech is notified promptly of
any Indemnification Claims; (b) Caltech has the sole right to control and defend or settle any litigation within the scope of this indemnity; and (c) all indemnified parties cooperate to the extent
necessary in the defense of any Indemnification Claims. The foregoing shall be the sole and exclusive remedy of Licensee for breach of Section 9.1. 

        9.4    Indemnification by Licensee.    Licensee shall indemnify, defend and hold harmless Caltech, its trustees,
agents and employees from and against any and all losses, damages, costs and expenses (including reasonable attorneys' fees) arising out of third party claims brought against Caltech relating to the
manufacture, sale, licensing, distribution or use of Licensed Products by or on behalf of Licensee or its Affiliates, except to the extent involving or relating to a material breach by Caltech of its
representations and warranties. 

10

 

        9.5    Certain Damages.    NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR
INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. 

 
 

ARTICLE 10
  TERM AND TERMINATION    
    

        10.1    Term.    This Agreement and the rights and licenses hereunder shall take effect on the Effective Date and
continue until the expiration, revocation, invalidation, or unenforceability of the last to expire patent under the Exclusively Licensed Patent Rights, unless earlier terminated pursuant to the terms
of this Agreement. 

        10.2    Termination for Monetary Breach.    Caltech shall have the right to terminate this Agreement and the rights
and licenses hereunder if Licensee fails to make any material payment due including patent expenses, minimum annual royalties or royalties hereunder after written notice from Caltech specifying
Licensee's failure provided that if Licensee disputes the asserted default, the matter will be submitted to arbitration as provided in Article 12 of this Agreement. In such event, Caltech shall
not have the right to terminate this Agreement until it has been determined in such arbitration proceeding that Licensee has failed to make a material payment and Licensee fails to cure such breach
within thirty (30) days after the conclusion of such arbitration proceeding. Upon any such termination, (a) Licensee shall have six (6) months to complete the manufacture of any
Licensed Products that are then works in progress for sale and to sell its inventory of Licensed Products, provided that Licensee pays the applicable royalties, and (b) any sublicenses shall
survive termination in accordance with Section 2.3. 

        10.3    Non-Monetary Termination for Breach.    If this Agreement is materially breached by either party,
the non-breaching party may elect to give the breaching party written notice describing the alleged breach. If the breaching party has not cured such breach within thirty (30) days
after receipt of such notice, the notifying party will be entitled, in addition to any other rights it may have under this Agreement, to terminate this Agreement and the rights and licenses hereunder
effective immediately; provided, however, that if either party receives notification from the other of a material breach and if the party alleged to be in default notifies the other party in writing
within thirty (30) days of receipt of such default notice that it disputes the asserted default, the matter will be submitted to arbitration as provided in Article 12 of this Agreement.
In such event, the non-breaching party shall not have the right to terminate this Agreement until it has been determined in such arbitration proceeding that the other party materially
breached this Agreement, and the breaching party fails to cure such breach within thirty (30) days after the conclusion of such arbitration proceeding. In the event a breach or default is not
capable of cure, the parties agree to negotiate a resolution in good faith. Notwithstanding the foregoing, with regard to breach of Section 7.1 only, the provisions of Section 7.3 shall
take precedence over any inconsistent provision in this Section 10.2. 

        10.4    Other Termination.    This Agreement may also be terminated, in whole or in part, as set forth in Sections 5.6
and 7.3. 

        10.5    Accrued Liabilities.    Termination of this Agreement for any reason shall not release any party hereto from
any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination, nor preclude either party from pursuing any
rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to such termination. 

        10.6    Survival.    The following shall survive any expiration or termination (in whole or in pat) of this Agreement:
(a) any provision plainly indicating that it should survive; (b) any royalty due and 

11

 

payable
on account of activity prior to the termination; and (c) sections or Articles 9, 10, 11, 12, 13, & 14.

 
 

ARTICLE 11
  CONFIDENTIALITY    
    

        11.1    Nondisclosure and Nonuse.    Each party agrees not to directly or indirectly disclose any confidential
information of the other party to any third party without the prior written consent of the other party, or to use any such confidential information for any purpose other than as contemplated by this
Agreement. The Technology, and the specification of any unpublished patent application, shall be considered confidential information of Caltech, except to the extent (if at all) the foregoing is
inherently disclosed in the normal course of use of a Licensed Product or Service. The terms of this Agreement shall be considered confidential information of both parties. Notwithstanding anything to
the contrary, confidential information of a party shall not include any information which: (a) is independently developed, without access to that party's confidential information, by the other
party; (b) is acquired by the other party from a third party who has the right to disclose such information; or (c) is or becomes part of the public domain (e.g., by publication of a
patent or by any other means) except via an unauthorized act or omission by the other party. 

        11.2    Permitted Disclosures.    Notwithstanding the foregoing, each party may disclose: (a) confidential
information as required by securities or other applicable laws or pursuant to governmental proceedings, provided that the disclosing party gives advance written notice to the other party and
reasonably cooperates therewith in limiting the disclosure to only those third parties having a need to know; (b) confidential information to that party's actual or prospective investors or
corporate partners, or to that party's accountants, attorneys, and other professional advisors; and (c) the fact that Licensee has been granted a license under the Exclusively Licensed Patent
Rights. Except with respect to the above third parties, Licensee agrees not to disclose information described in paragraph 11.1 to any third party unless under an appropriate nondisclosure
agreement. 

 
 

ARTICLE 12
  DISPUTE RESOLUTION    
    

        12.1 Except
for those issues and/or disputes described in Section 10.2, any dispute between the Parties concerning the interpretation, construction or application of
any terms, covenants or conditions of this Agreement shall be resolved by arbitration. 

        12.2 Arbitration
shall be in accordance with the rules of the American Arbitration Association, in effect on the Effective Date by a sole Arbitrator who shall be appointed
in accordance with the applicable AAA rules. Any other choice of law clause to the contrary in this Agreement notwithstanding, the arbitration shall be governed by the United States Arbitration Act, 9
U.S.C. Section 1-16. 

        12.3 Any
award made (i) shall be a bare award limited to a holding for or against a party and affording such remedy as is within the scope of the Agreement;
(ii) shall be accompanied by a brief statement (not to exceed ten (10) pages) of the reasoning on which the award rests; (iii) shall be made within four (4) months of the
appointment of the Arbitrator; (iv) may be entered in any court of competent jurisdiction; and (v) any award pertaining to a patent which is subsequently determined to be invalid or
unenforceable or otherwise precluded from being enforced, in a judgment rendered by a court of competent jurisdiction from which no appeal can or has been taken, may be modified as it relates to such
patent by any court of competent jurisdiction upon application by any party to the arbitration, however, under no circumstances shall Caltech be required to refund any monies paid under the terms of
this Agreement. 

12

 

        12.4 The
requirement for arbitration shall not be deemed a waiver of any right of termination under this Agreement and the Arbitrator is not empowered to act or make any
award other than based solely on the rights and obligations of the Parties prior to any such termination. 

        12.5 Each
party shall bear its own expenses incurred in connection with any attempt to resolve disputes hereunder, but the compensation and expenses of the Arbitrator shall
be borne equally. 

        12.6 The
Arbitrator shall not have authority to award punitive or other damages in excess of compensatory damages, and each party irrevocably waives any claim thereto. 

 
 

ARTICLE 13
  PRODUCT LIABILITY    
    

        13.1    Indemnification.    Licensee agrees that Caltech (including its trustees, officers, faculty and employees)
shall have no liability to Licensee, its Affiliates, their customers or any third party, for any claims, demands, losses, costs, or other damages which may result from personal injury, death, or
property damage related to the Licensed Products or Services ("Product Liability Claims"). Licensee agrees to defend, indemnify, and hold harmless
Caltech, its trustees, officers, faculty and employees from any such Product Liability Claims, provided that: (a) Licensee is notified promptly of any Product Liability Claims;
(b) Licensee has the sole right to control and defend or settle any litigation within the scope of this indemnity; and (c) all indemnified parties cooperate to the extent necessary in
the defense of any Claims. 

        13.2    Insurance.    Prior to such time as Licensee begins to manufacture, sell, license, distribute or use Licensed
Products, Licensee shall at its sole expense, procure and maintain policies of comprehensive general liability insurance in amounts not less than $1,000,000 per incident and $3,000,000 in annual
aggregate, and naming those indemnified under Section 13.1 as additional insureds. Such comprehensive general liability insurance shall provide: (a) product liability coverage; and
(b) broad form contractual liability coverage for Licensee's indemnification of Caltech under Section 13.1. In the event the aforesaid product liability coverage does not provide for
occurrence liability, Licensee shall maintain such comprehensive general liability insurance for a reasonable period of not less than five (5) years after it has ceased commercial distribution
or use of any Licensed Product. Licensee shall provide Caltech with written evidence of such insurance upon request of Caltech. 

        13.3    Loss of Coverage.    Licensee shall provide Caltech with notice at least fifteen (15) days prior to any
cancellation, non-renewal or material change in such insurance, to the extent Licensee receives advance notice of such matters from its insurer. If Licensee does not obtain replacement
insurance providing comparable coverage within ninety (90) days following the date of such cancellation, non-renewal or material change, Caltech shall have the right to terminate
this Agreement effective at the end of such ninety (90) day period without any additional waiting period; provided that if Licensee provides credible written evidence that is has used
reasonable efforts, but is unable, to obtain the required insurance, Caltech shall not have the right to terminate this Agreement, and Caltech instead shall cooperate with Licensee to either (at
Caltech's discretion) grant a limited waiver of Licensee's obligations under this Article or assist Licensee in identifying a carrier to provide such insurance or in developing a program for
self-insurance or other alternative measures. 

 
 

ARTICLE 14
  MISCELLANEOUS    
    

        14.1    Notices.    All notice, requests, demands and other communications hereunder shall be in English and shall be
given in writing and shall be: (a) personally delivered; (b) sent by telecopier, facsimile transmission or other electronic means of transmitting written documents with confirmation of
receipt; or (c) sent to the parties at their respective addresses indicated herein by registered or certified 

13

 

mail,
return receipt requested and postage prepaid, or by private overnight mail courier services with confirmation of receipt. The respective addresses to be used for all such notices, demands or
requests are as follows: 

	(a)
	If
to CALTECH, to: 

California
Institute of Technology

1200 East California Boulevard

Mail Code 210-85

Pasadena, CA 91125

ATTN: Director, Technology Transfer

Phone No.: (626) 395-3288

Fax No.: (626) 356-2486 

        Or
to such other person or address as Caltech shall furnish to Licensee in writing. 

	(b)
	If
to LICENSEE, to: 

Helicos
Biosciences Corp.

150 CambridgePark Drive

Cambridge, MA 02140

ATTN: President

Phone No.:

Fax No.: 

        If
personally delivered, such communication shall be deemed delivered upon actual receipt by the "attention" addressee or a person authorized to accept for such addressee; if transmitted
by facsimile pursuant to this paragraph, such communication shall be deemed delivered the next business day after transmission, provided that sender has a transmission confirmation sheet indicating
successful receipt at the receiving facsimile machine; if sent by overnight courier pursuant to this paragraph, such communication shall be deemed delivered upon receipt by the "attention" addressee
or a person authorized to accept for such addressee; and if sent by mail pursuant to this paragraph, such communication shall be deemed delivered as of the date of delivery indicated on the receipt
issued by the relevant postal service, or, if the addressee fails or refuses to accept delivery, as of the date of such failure or refusal. Any party to this Agreement may change its address for the
purposes of this Agreement by giving notice thereof in accordance with this Section 14.1 

        14.2    Entire Agreement.    This Agreement sets forth the complete agreement of the parties concerning the subject
matter hereof. No claimed oral agreement in respect thereto shall be considered as any part hereof. No amendment or change in any of the terms hereof subsequent to the execution hereof shall have any
force or effect unless agreed to in writing by duly authorized representatives of the parties. 

        14.3    Waiver.    No waiver of any provision, of this Agreement shall be effective unless in writing. No waiver shall
be deemed to be, or shall constitute, a waiver of a breach of any other provision of this Agreement, whether or not similar, nor shall such waiver constitute a continuing waiver of such breach unless
otherwise expressly provided in such waiver. 

14

  

        14.4    Severability.    Each provision contained in this Agreement is declared to constitute a separate and
distinct
covenant and provision and to be severable from all other separate, distinct covenants and provisions. It is agreed that should any clause, condition or term, or any part thereof, contained in this
Agreement be unenforceable or prohibited by law or by any present or future legislation then: (a) such clause, condition, term or part thereof, shall be amended, and is hereby amended, so as to
be in compliance therewith the legislation or law; but (b) if such clause, condition or term, or part thereof, cannot be amended so as to be in compliance with the legislation or law, then such
clause, condition, term or part thereof shall be severed from this Agreement all the rest of the clauses, terms and conditions or parts thereof contained in this Agreement shall remain unimpaired. 

        14.5    Construction.    The headings in this Agreement are inserted for convenience only and shall not constitute a
part hereof. Unless expressly noted, the term "include" (including all variations thereof) shall be construed as merely exemplary rather than as a term of limitation. 

        14.6    Counterparts/Facsimiles.    This Agreement may be executed in one or more counterparts, all of which taken
together shall be deemed one original. Facsimile signatures shall be deemed original. 

        14.7    Governing Law.    This Agreement, the legal relations between the parties and any action, whether contractual
or non-contractual, instituted by any party with respect to matters arising under or growing out of or in connection with or in respect of this Agreement shall be governed by and construed
in accordance with the internal laws of the State of California, excluding any conflict of law or choice of law rules that may direct the application of the laws of another jurisdiction. 

        14.8    No Endorsement.    Licensee agrees that it shall not make any form of representation or statement which would
constitute an express or implied endorsement by Caltech of any Licensed Product, and that it shall not authorize others to do so, without first having obtained written approval from Caltech, except as
may be required by governmental law, rule or regulation. 

        14.9    Transferability.    This Agreement shall be binding upon and inure to the benefit of any successor or assignee
of Caltech. This Agreement is not transferable by Licensee without the prior written consent of Caltech, and any attempted transfer shall be void, except that Licensee may transfer this Agreement
without the prior written consent of Caltech to any Affiliate or any successor of, or purchaser of substantially all of, the assets or operations of its business to which this Agreement pertains. Any
permitted transferee shall succeed to all of the rights and obligations of Licensee under this Agreement. 

        14.10    Export Regulations.    This Agreement is subject in all respects to the laws and regulations of the United
States of America, including the Export Administration Act of 1979, as amended, and any regulations thereunder. Licensee or its sublicensees will not in any form export, re-export, resell,
ship, divert, or cause to be exported, re-exported, resold, shipped, or diverted, directly or indirectly, any product or technical data or software of the other party, or the direct
product of such technical data or software, to any country for which the United States Government or any agency thereof requires an export license or other governmental approval without first
obtaining such license or approval 

        14.11    Force Majeure.    Neither party shall lose any rights hereunder or be liable to the other party for damages
or losses (except for payment obligations) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, Act of God, earthquake, flood, lockout,
embargo, governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence or
intentional conduct or misconduct of the nonperforming party, and such party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a party
be required to settle any labor dispute or disturbance. 

15

 

        IN WITNESS WHEREOF, the parties have caused this Agreement to be executed: 

	 	 	CALIFORNIA INSTITUTE OF TECHNOLOGY (Caltech)
	

Date: 11/21/03	
 	

By:	
 	

/s/ Lawrence Gilbert

	 	 	Name:	 	Lawrence Gilbert
	 	 	Title:	 	Director, Office of Technology Transfer
	

 	
 	

HELICOS BIOSCIENCES CORP.
	

Date: 11/30/03	
 	

By:	
 	

/s/ Stanley N. Lapidus

	 	 	Name:	 	Stanley N. Lapidus
	 	 	Title:	 	President

16

 
Exhibit A  

 Exclusively Licensed Patent Rights  

[***] 

PORTIONS
OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES
ACT; [***] DENOTES OMISSIONS. 

17

 
 
 

Exhibit B    
    
    Technology    
    

	Name
 
	 	Description

18

QuickLinks

Exhibit 10.7

LICENSE AGREEMENT

ARTICLE 1 DEFINITIONS

ARTICLE 2 LICENSE GRANT

ARTICLE 3 DISCLOSURE AND DELIVERY

ARTICLE 4 PROSECUTION OF PATENT APPLICATIONS AND PAYMENT OF PATENT COSTS

ARTICLE 5 ROYALTIES

ARTICLE 6 LICENSEE EQUITY INTEREST

ARTICLE 7 DUE DILIGENCE

ARTICLE 8 LITIGATION

ARTICLE 9 REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION

ARTICLE 10 TERM AND TERMINATION

ARTICLE 11 CONFIDENTIALITY

ARTICLE 12 DISPUTE RESOLUTION

ARTICLE 13 PRODUCT LIABILITY

ARTICLE 14 MISCELLANEOUS

Exhibit B Technology

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00118-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00118-of-00352.parquet"}]]